Lesson
Treat the Failing System Before Naming the Poison
The exact substance may be unknown while respiratory failure, shock, seizure, hypoglycemia, or hyperthermia is already causing injury. Toxicology begins with resuscitation and a disciplined exposure reconstruction.
- Physiologic stabilization
- Poison center
- Exposure history
- Mixed ingestion
- Intent and safety
Treat ventilation, circulation, seizure, temperature, and reversible metabolic threats.
Resolve product, ingredient, formulation, dose, route, time, intent, and coexposures.
Connect the evolving case to poison-center and medical-toxicology guidance.
Start with physiology
Assess responsiveness, airway protection, respiratory rate and effort, oxygenation, ventilation, perfusion, rhythm, temperature, glucose, and seizure activity. Give standard life support and time-critical empiric therapy when the clinical pattern supports it. An antidote never replaces ventilation, oxygenation, chest compressions, vasopressors, or correction of a lethal metabolic problem.
Reconstruct the exposure
Identify product, active ingredients, concentration, formulation, amount, route, time, intent, and coexposures. Collect containers, photographs, pill counts, pharmacy records, scene details, and collateral history. Account for extended-release products, combination tablets, transdermal systems, and delayed absorption.
Use experts early
Regional poison centers and medical toxicologists provide current, case-specific guidance. Share age, weight, pregnancy status, organ function, symptoms, vital signs, ECG, laboratory data, treatments, and response. Recontact them as the course changes.
Protect the person throughout care
Intentional poisoning requires safety precautions and qualified mental health assessment alongside medical care. In the NIMH adult ED pathway after a positive suicide screen, current suicidal thoughts require urgent evaluation and the patient must not be left alone. Denying a need for help does not establish safety. Assess plans, access to means, past attempts and support; disposition follows assessment. When discharge is appropriate, include a safety plan and securing dangerous medicines. Accidental poisoning should trigger storage, packaging, dosing, vision, cognition and caregiver review.
Make packaging part of prevention
Child-resistant does not mean childproof. Keep medicines secured out of children's sight and reach, reclose the safety cap after every use, and check that caregivers can operate it correctly. An adherence blister or pill organizer is not automatically child-resistant; confirm the actual package design rather than assuming a calendar label provides protection.
Resolve access needs without an assumed waiver
CPSC guidance requires special packaging for regulated oral prescription drugs unless an exemption or specific patient/prescriber request applies. Do not infer a blanket waiver from one prescription request. A prescriber's direction applies to that prescription and its refills; a patient may explicitly request conventional packaging for all prescriptions. Reassess preferences and household child access, including visitors. Tamper evidence and child resistance address different hazards.
Choose the right help channel
Collapse, seizure, difficulty breathing or inability to awaken requires immediate emergency activation (911 in the United States). For other poison questions, call 1-800-222-1222. The webPOISONCONTROL tool excludes self-harm, pregnancy, multiple-product exposures and ages outside 6 months through 79 years. Self-harm exposure needs immediate clinical evaluation, even before symptoms.
Quick check
Checking for saved practice…
Lesson
Reduce Exposure Without Creating a Second Injury
Decontamination is not a ritual. The route, substance, time, airway, gastrointestinal function, expected toxicity, and available evidence determine whether an intervention helps or harms.
- Route-specific first aid
- Button batteries
- Activated charcoal
- Urine alkalinization
- Hemodialysis
Protect rescuers and match irrigation or removal to skin, eye, inhaled, or swallowed toxin.
Use charcoal only when adsorption, timing, bowel function, and airway safety align.
Reserve alkalinization, multidose charcoal, and dialysis for compatible toxins and severity.
Do not delay eye irrigation
For an ordinary chemical splash, begin rinsing immediately with room-temperature water for at least 15 to 20 minutes and remove contact lenses. Seek poison-center guidance afterward; severe pain or visual symptoms need urgent evaluation after irrigation. Product-specific instructions can require additional measures.
Match first aid to the route
Remove contaminated clothing and irrigate skin or eyes according to the substance and expert guidance. Move inhalation victims to fresh air only when rescuers can do so safely. Do not place household chemicals, drops, or neutralizing agents into an exposed eye, ear, nose, or wound unless directed.
Treat button batteries as time critical
An esophageal battery can generate hydroxide and cause severe injury within about two hours. Obtain urgent imaging and remove an esophageal battery immediately. For a child at least 12 months old who can swallow and ingested a possible lithium coin cell within 12 hours, 10 mL of commercial honey every 10 minutes for up to six doses can slow injury while traveling to emergency care. It must not delay imaging or removal.
Keep battery mitigation within its boundaries
Do not delay emergency evaluation to obtain honey. Withhold it when swallowing is unsafe, the child is younger than 12 months, or ingestion may exceed 12 hours. Removal is urgent for an esophageal battery even after recent food or honey. Injury can progress after removal; the treating team determines monitoring and follow-up.
Use charcoal selectively
Charcoal is not routine treatment for every ingestion. The 2026 Clinical Toxicology Recommendations Collaborative uses poison-specific timing and risk assessment, sometimes supporting administration beyond the traditional one-hour window. Delayed absorption can justify later treatment; the clock alone cannot settle the decision. Protect the airway and assess bowel function, perforation risk, expected toxicity and alternatives.
Distinguish repeat dosing by purpose
An additional charcoal dose can complete gastrointestinal decontamination when absorption continues. Multiple-dose charcoal for enhanced elimination has a different purpose: increasing clearance of selected absorbed poisons. Document which goal is intended rather than treating every second dose as the same intervention.
Calculate grams before volume
The 2026 consensus uses 50 g for adult single or additional doses and 1 g/kg in children, capped at 50 g. For a prescribed dose in a 20-kg child, 20 kg times 1 g/kg equals 20 g. A verified 50 g/250 mL suspension contains 0.2 g/mL, so 20 g requires 100 mL. Confirm the actual formulation and indication before giving it.
Do not turn a schedule into an indication
For selected enhanced-elimination indications, the consensus describes the initial single dose followed by the same dose every 4 hours or half that dose every 2 hours. These are alternatives, not concurrent schedules. An appropriate dose does not override an unsafe airway, absent gut motility or an unsupported toxin indication; reassessment remains necessary.
Apply carbamazepine guidance by formulation
The 2026 consensus uses a 25 mg/kg ingested-dose threshold for single-dose charcoal: recommended through two hours for immediate-release and three hours for modified-release carbamazepine, with suggested windows through three and four hours, respectively. Other circumstances require individual assessment. For either formulation, multiple-dose elimination therapy is suggested above 40 mg/kg. These are ingested doses, not serum concentrations; airway protection and bowel function still determine feasibility.
Do not carry an old charcoal list into every exposure
An additional decontamination dose and multiple-dose elimination therapy need separate decisions. For carbamazepine, the consensus recommends an additional dose above 50 mg/kg for immediate-release and suggests it above 40 mg/kg for modified-release exposure. Quinine requires individualized assessment for both additional and multiple-dose use. Membership in a traditional multidose-charcoal mnemonic does not establish a universal indication.
Keep phenobarbital elimination tied to clinical severity
The 2026 charcoal consensus supports multiple-dose charcoal at a phenobarbital ingested-dose threshold of 50 mg/kg, provided airway and gastrointestinal conditions permit. This is not a threshold below which toxicity is excluded. Do not delay extracorporeal treatment for severe long-acting barbiturate poisoning: EXTRIP recommends it for prolonged coma, shock despite fluids, or persistent toxicity despite multiple-dose charcoal. It suggests treatment for concentrations that rise or remain elevated despite charcoal, or respiratory depression requiring ventilation. Intermittent hemodialysis is preferred; clinical improvement guides stopping.
Preserve airway safeguards
Do not intubate solely to give charcoal when clinically significant poisoning is not expected. In a potentially life-threatening ingestion, an expert risk-benefit assessment may support intubation to facilitate treatment. The 2026 consensus also advises against placing a nasogastric or orogastric tube solely for charcoal without endotracheal intubation.
Select bowel irrigation deliberately
Whole-bowel irrigation uses polyethylene glycol-electrolyte solution to move selected material through the gastrointestinal tract. It may be considered for substantial iron, lithium or potassium ingestion, selected modified-release products, or intact drug packets in body packers. It is contraindicated with obstruction, perforation, ileus, unstable circulation or a compromised unprotected airway. Evidence that removal improves clinical outcomes remains limited.
Keep ion trapping separate from treatment
Acidic urine can increase amphetamine excretion, but intentionally acidifying urine is not recommended treatment: worsening systemic acidosis can outweigh a clearance change. Do not generalize the weak-base mnemonic into a poisoning protocol. Urinary alkalinization is also not an amphetamine-clearance strategy.
Escalate elimination by mechanism
Urine alkalinization enhances elimination of selected weak acids such as salicylate. Multidose charcoal has narrow toxin-specific roles. Hemodialysis depends on toxicity, clinical trajectory, molecular characteristics, endogenous clearance, and the ability of the procedure to change outcome. Clinical deterioration can justify dialysis before a conventional concentration threshold is reached.
Quick check
Checking for saved practice…
Lesson
Read the Pattern, Then Challenge It
Toxidromes and targeted tests organize uncertainty. They guide urgent therapy, but mixed ingestions, delayed kinetics, and medical mimics mean the pattern must be revised as new evidence arrives.
- Toxidromes
- Pupils and secretions
- ECG
- Acid-base data
- Targeted testing
Map pupils, moisture, secretions, temperature, bowel activity, tone, reflexes, and clonus.
Separate QRS widening, QT prolongation, conduction block, and ventricular instability.
Read pH, anion gap, osmolar gap, lactate, and toxin levels as moving signals.
Recognize high-yield patterns
Opioid poisoning centers on respiratory depression. Cholinergic poisoning is wet with secretions and can include fasciculations and weakness. Anticholinergic poisoning is hot, dry, mydriatic, delirious, and retentive. Sympathomimetic poisoning is agitated, diaphoretic, hypertensive, and often hyperthermic. Serotonin toxicity features clonus and hyperreflexia in a compatible exposure.
Use the ECG as a toxicology test
Measure QRS, QT, rhythm, rate, and conduction. QRS widening with hypotension after a tricyclic or another sodium-channel blocker is a bicarbonate-responsive emergency. QT prolongation requires drug review, electrolyte correction, and rhythm surveillance but does not imply sodium-channel blockade by itself.
Interpret gaps across time
Anion gap, osmolar gap, pH, bicarbonate, lactate, ketones, and measured osmolality are time-dependent clues. A normal osmolar gap can occur late in toxic alcohol poisoning after the parent alcohol has become a toxic acid. Salicylate toxicity can produce respiratory alkalosis and metabolic acidosis together.
Know what the assay measures
Routine opiate immunoassays commonly target morphine and codeine; fentanyl may require a separate assay. A positive urine result does not establish current impairment or the dose taken. Treat suspected opioid respiratory depression from clinical findings without waiting for a test.
Order tests that change care
Bedside glucose, ECG, metabolic panel, acid-base data, kidney and liver function, pregnancy testing when relevant, and selected acetaminophen, salicylate, alcohol, iron, digoxin, or other levels are more useful than an indiscriminate screen. Routine urine immunoassays miss important agents and can produce false positives.
Quick check
Checking for saved practice…
Lesson
Interrupt Acetaminophen Injury Before the Liver Declares It
A patient can feel well while toxic metabolism is progressing. The decisive work is accurate exposure classification, correctly timed concentrations, early acetylcysteine, and treatment that continues until stopping criteria are met.
- NAPQI
- Rumack-Matthew nomogram
- Acetylcysteine
- Extended release
- Liver failure
Known-time acute, unknown-time, repeated, delayed, or extended-release ingestion.
Use a level drawn 4 to 24 hours from the start of a reliably timed acute exposure.
Start early, monitor response, and continue until biochemical and clinical stopping criteria are met.
Connect dose to toxic metabolism
Most acetaminophen is conjugated to nontoxic products. A smaller CYP pathway forms NAPQI, which glutathione normally detoxifies. With sufficient exposure, conjugation and glutathione capacity are overwhelmed, NAPQI binds hepatic proteins, and centrilobular injury can progress to liver failure.
Use the nomogram in its lane
Use the revised nomogram with a reliable start time and a concentration drawn 4 to 24 hours after ingestion began. US/Canada consensus includes acute exposures spread over less than 24 hours; staggered doses alone do not exclude its use. Ingestions spanning more than 24 hours, unknown timing, and unreliable histories require separate pathways. Extended-release or delayed absorption may require repeat levels.
Decide when acetylcysteine must begin
For a reliable acute exposure, start treatment when a concentration obtained 4 to 24 hours after ingestion is on or above the nomogram treatment line, which begins at 150 micrograms/mL at four hours. Do not apply that single concentration cutoff at every later time. If an acute dose above 200 mg/kg or 10 g is strongly suspected and waiting for the result would delay treatment beyond eight hours, start acetylcysteine while awaiting testing.
Use a separate pathway for repeated exposure
For ingestion spanning more than 24 hours, the US/Canada consensus directs acetylcysteine when acetaminophen exceeds 20 micrograms/mL or AST/ALT is abnormal. Do not reset the clock to the last dose or require both laboratory findings. Unknown or unreliable timing also requires its own assessment rather than an invented nomogram time.
Treat an unreliable clock as a separate pathway
For unknown or unreliable timing, obtain acetaminophen and a metabolic panel rather than plotting an invented time. The US/Canada consensus directs acetylcysteine when the concentration exceeds 10 micrograms/mL or AST/ALT is abnormal beyond the patient's baseline. A concentration of 10 or less with normal or baseline enzymes does not require acetylcysteine under this pathway; it does not establish overall discharge safety.
Repeat testing when absorption may be delayed
For US/Canada eight-hour extended-release products, a level drawn 4 to 12 hours after ingestion that is above 10 micrograms/mL but below the treatment line requires another level 4 to 6 hours later. With opioid or anticholinergic coingestion, apply that repeat interval when a 4-to-24-hour level is above 10 but below the line and those drugs are producing clinical effects. A treatment-line result warrants acetylcysteine rather than waiting for the repeat. International modified-release products can behave differently; identify the formulation and consult toxicology.
Separate charcoal from acetylcysteine decisions
The 2026 charcoal consensus recommends single-dose charcoal for immediate-release acetaminophen exposures of at least 200 mg/kg within 2 hours and suggests it through 3 hours; modified-release exposures at that threshold have a longer window, recommended through 5 hours and suggested through 6 hours. Other circumstances need individual assessment. These charcoal thresholds do not rule out liver injury or replace acetylcysteine criteria.
Name the reason for another charcoal dose
For acetaminophen, that consensus recommends an additional decontamination dose at reported exposures of at least 350 mg/kg immediate-release or 300 mg/kg modified-release. It recommends against multiple-dose charcoal for enhanced elimination of either formulation. Discuss ongoing absorption and contraindications with toxicology; do not substitute a charcoal course for acetylcysteine or serial laboratory assessment.
Keep the oral formulation distinct
The traditional oral course uses 140 mg/kg once, then 70 mg/kg every 4 hours for 17 maintenance doses, beginning 4 hours after loading. Repeat an oral dose vomited within 1 hour. The oral/inhalation solution is not injectable. For the 20% product, add three parts appropriate diluent to one part concentrate to obtain 5%; prepare fresh and use within 1 hour. Persistent vomiting or inability to protect the airway requires reassessment of route with the treating team.
Reconcile legacy labeling with current care
Some oral-product labels retain instructions for ipecac, routine lavage and stopping acetylcysteine when hepatic encephalopathy develops. These are not the contemporary care pathway taught here. Do not induce vomiting; select decontamination with toxicology guidance. Worsening liver failure requires urgent critical-care and transplant assessment, with acetylcysteine continued when indicated by current guidance. Do not stop a needed antidote solely because encephalopathy appears.
Choose the IV regimen deliberately
Acetadote three-bag dosing is 150 mg/kg over 1 hour, 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (21 hours total). At 41 kg or more, the alternative is 200 mg/kg over 4 hours then 100 mg/kg over 16 hours (20 hours). Both total 300 mg/kg. Patients 40 kg or less require the three-bag regimen; dosing below 5 kg needs specialist guidance. Comparable hepatoprotection between regimens is not established. Three bags may be preferred with large ingestion or early severe injury.
Check dose, volume, and delivery separately
Acetadote is IV-only, 200 mg/mL concentrate requiring dilution. Use its weight-specific diluent table; do not confuse diluent volume with total admixture volume. Reduce fluid for small or fluid-restricted patients. At 100 kg or more, labeled doses are capped: three bags contain 15 g, 5 g and 10 g; two bags contain 20 g and 10 g. Confirm pump settings at every bag change.
Respond to hypersensitivity
Stop a severe reaction and treat immediately. Carefully restarting after symptoms resolve is sometimes possible; recurrent or worsening reactions require alternative management. Involve toxicology rather than abandoning needed rescue.
Stop by recovery criteria
ACMT 2026 requires all of the following before stopping IV acetylcysteine: acetaminophen below 10 micrograms/mL, AST/ALT at the patient's baseline or decreased 25% to 50% from peak, INR below 2, and improving prognostic markers such as creatinine, lactate, pH and phosphate. Interpret these with clinical recovery and toxicology input. A finished bag or low acetaminophen level alone is insufficient. Continue therapy and reassess when any recovery requirement remains unmet.
Escalate high-risk poisoning
Marked exposure, acidosis, coma, delayed absorption or liver failure requires urgent poison-specialist and critical-care input. Treatment may need to extend beyond the routine course, and severe organ failure may require extracorporeal support or transplant evaluation.
Separate acetaminophen removal from routine antidote care
EXTRIP recommends removal at acetaminophen above 900 mg/L with altered mental status, metabolic acidosis and elevated lactate despite acetylcysteine. Without acetylcysteine, its triggers include above 1000 mg/L alone or above 700 mg/L with that clinical pattern. These unusual emergencies require immediate expert coordination, not withholding acetylcysteine to meet a threshold. Reported dose alone is insufficient; when acetylcysteine is given, concentration alone is also insufficient. Intermittent hemodialysis is preferred, with treatment continued until sustained clinical improvement.
Reconcile the dialysis pathway and antidote rate
The 2023 US/Canada consensus uses acetaminophen at least 900 micrograms/mL with acidosis or altered consciousness attributable to toxicity, a broader formulation than EXTRIP's combined findings. Confirm the selected pathway with toxicology. It specifies IV acetylcysteine at least 12.5 mg/kg/hour during hemodialysis; oral dosing does not require adjustment. Dialysis supplements rather than replaces antidote treatment. Numerically, 1 mg/L equals 1 microgram/mL.
Calculate before programming
For a 60-kg patient prescribed the three-bag course: 60 × 150 = 9,000 mg; 60 × 50 = 3,000 mg; 60 × 100 = 6,000 mg. Total: 18,000 mg. At 200 mg/mL, withdraw 45, 15 and 30 mL of concentrate respectively, then dilute using the applicable preparation instructions. These withdrawal volumes are not pump rates. The final bag delivers 6,000 mg over 16 hours, or 375 mg/hour; convert to mL/hour only after confirming the final admixture concentration.
Quick check
Checking for saved practice…
Lesson
Restore Breathing, Then Protect Against Recurrence
Opioid death is a ventilation problem. Naloxone can reverse it temporarily, but rescue breathing, repeat dosing, observation, and emergency care remain essential. Most other sedatives depend on supportive care.
- Respiratory depression
- Naloxone
- Renarcotization
- Flumazenil
- Supportive care
Support oxygenation and ventilation before and during antagonist delivery.
Give promptly and repeat with a new device when response is absent or respiratory depression returns.
The opioid can outlast naloxone, so emergency care and continued observation remain essential.
Recognize the respiratory emergency
Slow, shallow, irregular, or absent breathing with reduced responsiveness is enough to act on suspected opioid exposure. Cyanosis and pinpoint pupils can occur but are not required. Ventilation and oxygenation begin immediately while naloxone is obtained.
Use naloxone as one part of rescue
Give the available formulation promptly and activate emergency care. Current intranasal labeling permits another single-use device every 2 to 3 minutes when the patient does not respond or relapses. Continue rescue breathing or CPR as indicated. Partial agonists can require repeated or higher total exposure under clinical guidance.
Match resuscitation to breathing and circulation
A trained rescuer who identifies a definite pulse with respiratory arrest provides breaths or bag-mask ventilation and an opioid antagonist. A lay rescuer finding an unresponsive person who is not breathing normally provides CPR with breaths. In known or suspected cardiac arrest, prioritize standard resuscitation; antagonist delivery must not interrupt compressions, ventilation or emergency activation. Do not wait for a spray to work before supporting breathing.
Teach the actual nasal device
OTC Narcan contains 4 mg naloxone hydrochloride in one 0.1-mL spray. Give the whole device into one nostril; do not prime, test or reuse it. If there is no response, repeat with a new device every 2-3 minutes; give another dose for recurrent marked sleepiness or respiratory depression. Stay until emergency responders arrive. Other brands and routes require their own instructions; a device is not a titratable IV syringe.
Calculate naloxone infusion from the response
For recurrent depression managed in a monitored clinical setting, AHA lists an IV infusion of two thirds of the effective waking dose per hour, titrated to breathing and airway protection. If an effective IV reversal dose is established as 1.2 mg, the starting calculation is 0.8 mg/h. With a pharmacy-prepared final concentration of 0.04 mg/mL, this equals 20 mL/h. The example assumes a documented effective IV dose; do not substitute the nominal milligrams sprayed into the nose or use the calculation as a fixed stopping rule.
Distinguish nalmefene from naloxone
Prescription OPVEE delivers 2.7 mg nalmefene per nasal device and is labeled for ages 12 and older. It uses a new, unprimed device for each dose, with repeat dosing every 2-5 minutes if needed. Its longer action does not eliminate recurrent depression, emergency care or observation. Attempts to overcome antagonist-induced withdrawal with more opioids can cause fatal intoxication.
Do not infer superiority from receptor affinity
The ACMT/AACT position statement advises that nalmefene should not replace naloxone as the primary antidote, citing limited comparative clinical evidence and concern for prolonged precipitated withdrawal. AHA 2025 likewise describes stronger clinical evidence for naloxone. Product approval, receptor affinity and volunteer pharmacology do not by themselves establish better outcomes in community overdose.
Keep rescue supply usable
Store Narcan according to its label: 2-25 degrees C, protected from light; avoid freezing or excessive heat above 40 degrees C. Replace expired stock through routine readiness checks. ACMT's March 2026 statement supports using expired naloxone during suspected overdose when unexpired drug is unavailable. This emergency exception is not a universal shelf-life extension or a guarantee of full potency; continue resuscitation and emergency care.
Expect recurrence and withdrawal
Many opioids last longer than naloxone, so respiratory depression can return. Continue observation and repeat dosing. Naloxone can precipitate acute withdrawal, but this risk does not justify withholding treatment from life-threatening respiratory depression.
Reserve flumazenil for selected patients
Supportive care remains central. AHA permits selected use for pure benzodiazepine respiratory depression when contraindications are absent, including carefully assessed procedural sedation. In suspected combined opioid and benzodiazepine poisoning, give naloxone first while supporting ventilation. Flumazenil has no role in benzodiazepine-associated cardiac arrest and can cause seizures or arrhythmias in high-risk patients. An unknown exposure history is not evidence that those risks are absent.
Check what the benzodiazepine is protecting
The label contraindicates flumazenil when benzodiazepines are controlling a life-threatening condition such as status epilepticus or raised intracranial pressure, with signs of serious cyclic-antidepressant overdose, or with hypersensitivity to flumazenil or benzodiazepines. Chronic dependence and recent repeated parenteral benzodiazepines increase seizure risk. Reversal can remove anticonvulsant protection; prepare to manage seizures and maintain airway support.
Separate pediatric labeling from guideline use
The FDA-labeled pediatric indication is reversal of benzodiazepine conscious sedation at ages 1-17. Pediatric overdose safety and efficacy are not established in the label. AHA nevertheless supports carefully selected pediatric pure-benzodiazepine poisoning without contraindications. This is a guideline-supported decision outside that labeled indication, not authorization to apply routine reversal to every sedated child.
Titrate flumazenil only after selecting the patient
For a selected adult overdose, the reviewed 0.1 mg/mL label starts with 0.2 mg IV over 30 seconds. After waiting 30 seconds, inadequate response permits 0.3 mg over 30 seconds, followed if needed by 0.5 mg over 30 seconds at one-minute intervals to a cumulative 3 mg. Only rarely, with a partial response at 3 mg, is further slow titration to 5 mg considered. This is not one rapid bolus and is distinct from procedural-sedation dosing. A 0.2-mg dose is 2 mL at the stated concentration.
Reassess instead of escalating indefinitely
The label says that no response five minutes after a cumulative 5 mg makes benzodiazepines unlikely to be the principal cause of sedation; further flumazenil is unlikely to help. For adult overdose resedation, repeat treatment may be given at 20-minute intervals, with no more than 1 mg per repeat treatment at 0.5 mg/min and no more than 3 mg in an hour. Recheck the cause of deterioration and contraindications while maintaining respiratory support.
Continue monitoring after reversal
Flumazenil does not reverse opioids, ethanol or barbiturates. Initial awakening does not prove sustained recovery; resedation and respiratory depression require continued monitoring and support. The label advises reducing repeat-dose size or frequency in hepatic disease. Do not use an empiric flumazenil challenge to diagnose unexplained ICU sedation.
Interpret pediatric benzodiazepine recovery clinically
The RCH pediatric pathway notes that deep coma after an apparently isolated benzodiazepine ingestion should prompt investigation for other substances. Serum benzodiazepine concentrations correlate poorly with clinical severity. Persistent intoxication beyond four hours calls for admission. Discharge consideration after an isolated ingestion requires clinical recovery, including normal consciousness and ability to ambulate; the observation clock alone is insufficient. Deliberate ingestion requires a mental health risk assessment. These are named institutional criteria, not a universal discharge rule for mixed poisoning.
Make observation and discharge a clinical decision
After opioid reversal, AHA calls for healthcare observation until recurrence risk is low and consciousness and vital signs are normal. There is no universally established observation duration, particularly in children. Long-acting or sustained-release exposures and repeated rescue requirements change the plan. Provide an opioid antagonist and teaching at discharge to the patient or appropriate caregiver.
Quick check
Checking for saved practice…
Lesson
Separate Ethanol Intoxication, Thiamine Deficiency and Withdrawal
Treat immediate physiologic threats while identifying nutritional and withdrawal risks.
- Glucose
- Ventilation
- Thiamine
- Wernicke encephalopathy
- Withdrawal
Treat the immediate threat before completing the exposure history.
Distinguish prevention from treatment of suspected Wernicke disease.
A detectable ethanol level does not settle the diagnosis.
Establish what was swallowed
Confirm the product, alcohol type, amount, timing and coexposures. A high ethanol level does not explain every altered examination: assess trauma, hypoglycemia and other drugs. Methanol, ethylene glycol and isopropanol require their own exposure pathways.
Support breathing, glucose and temperature
Treatment is primarily supportive. Check glucose promptly, support ventilation when depressed, correct volume depletion and hypothermia, and reassess consciousness. Children can develop substantial hypoglycemia or hypothermia after relatively small exposures. Thiamine does not reverse ethanol sedation.
Give glucose and thiamine without a harmful delay
Treat urgent hypoglycemia immediately. ASAM permits glucose and thiamine in either order or concurrently. In alcohol withdrawal, its preventive regimen is typically thiamine 100 mg IV or IM daily for 3 to 5 days, with parenteral administration preferred in poor nutrition, malabsorption or severe withdrawal complications. This preventive regimen is not a universal treatment dose for suspected Wernicke encephalopathy.
Treat suspected Wernicke disease as a separate emergency
In an at-risk patient, confusion, gait disturbance or abnormal eye movements warrant urgent assessment and parenteral treatment. The 2025 UK hospital guideline uses thiamine 300 to 500 mg IV three times daily for 3 to 5 days with daily review; persistent symptoms may require continued parenteral treatment. This is an attributed UK treatment protocol. Follow the applicable hospital pathway, monitor for anaphylaxis, check magnesium and correct deficiency.
Do not exclude withdrawal because ethanol is detectable
ASAM states that a positive blood alcohol concentration neither establishes nor excludes withdrawal. Assess the pattern of reduced intake, prior complicated withdrawal and current findings. A withdrawal scale alone is not a diagnostic test; manage intoxication, withdrawal and alternative causes of delirium according to the clinical assessment.
Use recovery and safety for disposition
The RCH pediatric pathway requires normal consciousness, glucose, temperature and relevant investigations before discharge consideration. Deliberate ingestion also requires a risk assessment and appropriate follow-up. A falling alcohol concentration alone does not demonstrate that a child is ready to leave.
Quick check
Checking for saved practice…
Lesson
Treat the Mechanism Behind Poisoned Shock
Bradycardia, wide-complex dysrhythmia, and shock can look similar at the monitor while arising from very different toxic mechanisms. ECG, glucose, perfusion, ventricular function, and exposure history guide therapy.
- Beta blockers
- Calcium-channel blockers
- High-dose insulin
- Digoxin
- Sodium-channel blockade
Use ECG, glucose, perfusion, and ventricular function to identify the dominant failure.
Connect calcium, insulin, Fab, bicarbonate, vasopressors, or other therapy to the toxin.
Mobilize invasive monitoring, toxicology, and extracorporeal support before collapse.
Differentiate beta-blocker and calcium-channel blocker physiology
Both can produce bradycardia, conduction delay, myocardial depression, and shock. Hypoglycemia can accompany selected beta blockers, while hyperglycemia supports severe calcium-channel blocker toxicity. Calcium, glucagon, high-dose insulin, vasopressors, and other therapies are selected from the toxin and hemodynamic phenotype.
Separate the treatment recommendations
The 2025 AHA guidance recommends vasopressors for hypotension in either poisoning. For life-threatening calcium-channel-blocker hypotension, it also recommends high-dose insulin. For beta-blocker poisoning, insulin is recommended when hypotension is refractory to vasopressors. Do not make a failed glucagon trial a universal prerequisite for insulin.
Look beyond beta blockade on the ECG
Propranolol can also block sodium channels and widen the QRS; sotalol blocks potassium channels and can prolong the QT with torsades risk. These are different electrophysiologic problems. Identify the agent and follow serial ECGs rather than treating every beta-blocker exposure as isolated bradycardia.
Select dialysis by the drug and clinical course
AHA says hemodialysis may be reasonable in life-threatening atenolol, nadolol or sotalol poisoning. Its supporting text notes limited evidence, particularly for nadolol and children. EXTRIP suggests extracorporeal removal for severe atenolol or sotalol poisoning with kidney impairment and refractory bradycardia plus hypotension; recurrent torsades is another qualifying feature for sotalol. A prolonged QT alone is insufficient. EXTRIP makes no recommendation for or against removal with normal kidney function and recommends against it for propranolol poisoning. When indicated, intermittent hemodialysis is preferred, with cessation based on clinical improvement. Discuss the specific exposure with toxicology and nephrology; dialysis for toxin removal and ECMO for circulatory support have different purposes.
Give adjuncts their proper role
Glucagon bolus followed by infusion is reasonable for symptomatic beta-blocker bradycardia or hypotension; nausea and vomiting are common. Its usefulness in CCB poisoning is uncertain. Calcium is reasonable for CCB toxicity but often insufficient alone. Lipid emulsion is not routine treatment for either class; AHA describes uncertain benefit in refractory shock from beta-blocker or CCB poisoning.
Operate high-dose insulin safely
AHA's dosing table lists regular human insulin 1 unit/kg initially, then 1 to 10 units/kg/hour with expert titration. Use an infusion pump and dedicated lumen, verify the final concentration and track response. Follow glucose, potassium, perfusion and fluid balance. This is a poisoning regimen, not an ordinary diabetes correction or DKA order.
Calculate units before pump volume
For a prescribed 1 unit/kg/hour infusion in a 70-kg patient, the dose is 70 units/hour. At a verified final concentration of 5 units/mL, the pump delivers 14 mL/hour. At 1 unit/mL, the same dose requires 70 mL/hour. Recalculate whenever the prepared concentration changes; do not confuse the stock vial concentration with the final infusion.
Plan glucose support independently
Utah Poison Control's protocol targets glucose 100 to 200 mg/dL and checks it every 10 to 15 minutes while titrating dextrose. Initial hyperglycemia does not remove later risk. If 20 g/hour is prescribed, D10 (0.1 g/mL) requires 200 mL/hour. Concentrated dextrose can reduce volume but requires appropriate vascular access and pharmacy safeguards.
Monitor beyond stopping insulin
Insulin shifts potassium into cells; a falling serum value does not necessarily represent a matching total-body loss. Replace cautiously under the toxicology protocol, using serial results, renal function and ECG. Glucose requirements can increase as perfusion recovers and can persist after insulin stops. Continue monitoring and adjust dextrose to measured need rather than stopping both infusions together automatically.
Do not exchange calcium salts gram for gram
AHA's adult initial-dose table pairs 2 g calcium chloride with 6 g calcium gluconate, each supplying about 28 mEq calcium. At 100 mg/mL, those are 20 mL and 60 mL respectively. Calcium chloride should use central access, especially in children. Track ionized calcium and hemodynamic response; verify compatibility before sharing an infusion line.
Neutralize life-threatening digoxin
Digoxin immune Fab is used for life-threatening or potentially life-threatening digitalis toxicity. Dose from the known ingestion or concentration when reliable, but do not delay for perfect data in ventricular dysrhythmia, severe hyperkalemia, or major instability. Total digoxin assays after Fab can be misleading.
Do not turn an empiric dose into a ceiling
The DigiFab label's 20-vial regimen applies to acute toxicity when the amount and concentration are unavailable; it is not a universal maximum. Chronic toxicity without a level has a different labeled regimen. Known-dose or appropriately timed concentration calculations and persistent or recurrent toxicity can require a different amount. Each 40-mg vial binds about 0.5 mg digoxin. Follow the full calculation and poison-center advice rather than applying 20 vials to every patient.
Recognize sodium-channel blockade
Tricyclic antidepressants and other membrane-active drugs can widen the QRS, lower blood pressure, trigger seizures, and cause ventricular dysrhythmias. Sodium bicarbonate is directed at the sodium-channel and acidemia problem. Serial ECG and hemodynamic response guide repeated treatment.
Do not generalize charcoal repetition to tricyclics
For tricyclic antidepressant ingestions at a 10-mg/kg threshold, the 2026 consensus recommends single-dose charcoal through 2 hours and suggests it through 3 hours. Other circumstances need individual assessment; use beyond 6 hours is discouraged. An additional dose requires individualized assessment, while multiple-dose enhanced elimination is discouraged. Charcoal must not displace airway protection or treatment of seizures, shock and sodium-channel blockade.
Separate bicarbonate dose from solution volume
AHA 2025 lists an initial adult dose of 50-150 mEq and pediatric dose of 1-3 mEq/kg for critical sodium-channel toxicity; pediatric doses should not exceed adult doses. These ranges require bedside titration and toxicology guidance. A 20-kg child prescribed 2 mEq/kg needs 40 mEq. At 0.5 mEq/mL, that is 80 mL; at 1 mEq/mL, it is 40 mL. Both concentrations are hypertonic. Verify the actual product rather than treating a syringe or vial as a unit of dose.
Calculate an infusion only after choosing its indication
AHA lists a 150 mEq/L infusion at 1-3 mL/kg/h. For a prescribed 2 mL/kg/h in a 70-kg adult, the pump rate is 140 mL/h, delivering 21 mEq/h at 0.15 mEq/mL. Do not enter 140 mEq/h. Continued boluses versus infusion after the initial response have no established superiority; follow the patient's ECG, perfusion and laboratory trajectory.
Do not chase the QRS with unlimited bicarbonate
Sodium loading and alkalinization both contribute. AHA describes debate between a pH near 7.50 and physiologic response as treatment endpoints. Avoid serum sodium above 155 mEq/L or pH above 7.55; monitor potassium and chloride as well. Persistent instability at a biochemical limit calls for expert reassessment, not automatic additional bicarbonate. Controlled ventilation can assist alkalinization in an already mechanically ventilated patient.
Escalate refractory toxicity deliberately
AHA considers extracorporeal life support reasonable for refractory cardiogenic shock. Lidocaine may be considered for severe class Ia/Ic blocker cardiotoxicity. Lipid emulsion is a possible rescue after other modalities fail, with limited and inconsistent evidence; it is not routine first-line treatment for every lipophilic oral overdose. Local-anesthetic toxicity has its own lipid-rescue pathway.
Quick check
Checking for saved practice…
Lesson
Calculate Fab From the Right Exposure and Reassess the Patient
Digoxin immune Fab binds drug; it does not make every measured digoxin concentration disappear. The exposure history, sample timing, dose method and clinical response must remain connected.
- Digoxin versus digitoxin
- Body-load calculation
- Serum-based estimate
- Preparation
- Post-Fab monitoring
Estimate body load from the formulation and credible history.
Calculate and prepare the prescribed antibody-fragment dose.
After Fab, interpret the laboratory result through binding and clinical response.
Treat life-threatening toxicity promptly
AHA recommends Fab for life-threatening digoxin or digitoxin poisoning. The DigiFab label also covers potentially life-threatening digoxin toxicity. Dangerous ventricular rhythms, progressive bradycardia or heart block and rapidly progressive toxicity with hyperkalemia can require treatment before a perfect dose estimate is available. Evaluate other causes when adequate treatment produces no response.
Use the detailed body-load method
Each 40-mg Fab vial binds approximately 0.5 mg digoxin. The label's detailed tablet method estimates absorbed load as swallowed digoxin milligrams times 0.8, then divides by 0.5 mg/vial. Its capsule method assumes the swallowed amount approximates body load. The abbreviated table omits this formulation detail. State the method rather than silently mixing estimates.
Work a tablet example
For a stipulated exposure of 30 tablets containing 0.25 mg each, the swallowed amount is 7.5 mg. Using the label's 0.8 tablet factor gives 6 mg estimated body load; 6 divided by 0.5 gives 12 vials. This calculation assumes the history and product are correct. It is not a reason to delay emergency treatment or a universal dose for uncertain exposure.
Use a concentration only when interpretable
The labeled digoxin estimate is serum concentration in ng/mL times weight in kg divided by 100, giving vials. A 70-kg patient with an interpretable pre-Fab concentration of 3 ng/mL yields 2.1 vials, usually rounded upward to 3 for full neutralization. Serum-tissue equilibration takes at least 6 to 8 hours after a dose. Do not insert an early or post-Fab total level into this calculation. Digitoxin uses a different denominator: 1000.
Distinguish empiric regimens and clinical titration
The label's unknown-amount acute regimen is 20 vials, starting with 10 and adding 10 if needed; this is not a maximum. For chronic toxicity without a level, it lists 6 vials for adults and children at least 20 kg and 1 vial below 20 kg. AHA notes differing regimens and uncertainty about ideal empiric dosing. Toxicology may individualize treatment; full-neutralization arithmetic and the selected clinical dose are not always identical.
Prepare Fab, not digoxin
Reconstitute each 40-mg vial with 4 mL sterile water for injection, yielding approximately 10 mg/mL Fab. Gently mix, inspect and dilute for infusion with 0.9% sodium chloride as directed. Use promptly; the label permits up to 4 hours refrigerated if not used immediately. Infuse over at least 30 minutes, except that imminent cardiac arrest can justify bolus delivery with greater reaction risk.
Handle small doses explicitly
For very small pediatric doses, the label permits adding 36 mL isotonic saline to the reconstituted vial to obtain 40 mL at 1 mg/mL. A prescribed 8-mg dose then occupies 8 mL, rather than 0.8 mL at 10 mg/mL. Confirm Fab milligrams, concentration and measurement device; never confuse Fab mass with the digoxin mass it binds.
Read response without trusting total digoxin
After Fab, a total digoxin result may rise because it includes bound drug. Follow ECG, blood pressure, clinical status and frequent potassium; reversal can produce a rapid potassium fall. Severe renal impairment warrants prolonged surveillance for recurrence, with free digoxin testing considered when useful. Watch for hypersensitivity and worsening heart failure or atrial fibrillation as digoxin's therapeutic action is removed.
Distinguish evidence across cardiac glycosides
AHA 2025 recommends digoxin-Fab for life-threatening digoxin or digitoxin poisoning. It considers Fab reasonable for life-threatening yellow oleander or Bufo toad poisoning; support for other cardiac glycosides is weaker. Plant and toad exposures do not have one established equivalent digoxin dose. Identify the source, follow ECG and potassium, and obtain toxin-specific dosing advice. The optimal empirical Fab dose during cardiac arrest remains uncertain.
Do not substitute dialysis for the antidote
AHA does not recommend extracorporeal removal to treat cardiac-glycoside poisoning. Renal replacement may still be needed for a separate indication. Fab use for other cardiac glycosides, including plant or toad toxins, requires toxin-specific expert dosing; do not reuse the digoxin concentration formula indiscriminately.
Quick check
Checking for saved practice…
Lesson
Recognize LAST and Use the Correct Rescue Pathway
Local-anesthetic systemic toxicity (LAST) is a resuscitation emergency. Neurologic toxicity and cardiovascular collapse may appear together or separately; a missing classic warning symptom does not make the exposure safe.
- LAST recognition
- 20% lipid emulsion
- Dose and rate units
- Modified resuscitation
- Ongoing observation
Calculate the initial volume and its delivery time.
Convert by 60 when the pump displays mL per hour.
Count boluses and infusions together against the protocol limit.
Recognize a systemic emergency
After local-anesthetic exposure, seizure, altered consciousness, conduction delay, ventricular arrhythmia or collapse should raise concern for LAST. Do not require neurologic warning signs before treating cardiovascular toxicity. Prevent hypoxia and acidemia; use benzodiazepines for seizures. AHA recommends intravenous lipid emulsion for life-threatening local-anesthetic poisoning.
Distinguish rescue from routine elimination
Lipid treatment is a toxin-specific rescue intervention, not a general method for clearing any lipid-soluble drug. Do not infer an indication from lipophilicity alone. AHA describes uncertain benefit in refractory beta-blocker shock; consult toxicology rather than transferring the LAST pathway to every cardiotoxic overdose.
Coordinate lipid with other rescue measures
Outside LAST, AHA considers lipid a possible option for life-threatening sodium-channel-blocker poisoning after other treatments fail; evidence is limited. Benefit in refractory beta-blocker or calcium-channel-blocker shock remains uncertain. Discuss lipid with toxicology and the ECMO team when mechanical support is being considered: reported complications include oxygenator malfunction and circuit aggregation. Lipid exposure does not automatically preclude ECMO, but the team needs the administered dose and timing.
Use the intended formulation
Use 20% intravenous lipid emulsion under the LAST protocol. Propofol is not a substitute: trying to deliver a rescue lipid quantity through propofol would also deliver a dangerous anesthetic dose. AHA notes that the ideal lipid regimen is not established by strong dosing evidence; ASRA supplies a practical bedside checklist.
Read the weight branch and units
ASRA's under-70-kg branch uses approximately 1.5 mL/kg over 2 to 3 minutes, followed by 0.25 mL/kg/min. Its over-70-kg branch uses about 100 mL over 2 to 3 minutes, then about 250 mL over 15 to 20 minutes. Persistent instability calls for a repeat bolus and doubled infusion. Track all lipid against the 12 mL/kg maximum; this maximum is not a starting bolus.
Check the pump calculation
For a prescribed under-70-kg regimen in a 60-kg patient: 1.5 times 60 gives a 90-mL bolus. The initial infusion is 0.25 times 60, or 15 mL/min, equivalent to 900 mL/hour. A doubled rate is 30 mL/min. The cumulative maximum is 720 mL across bolus and infusion. Reassessment, not arithmetic alone, determines what is delivered.
Modify the usual resuscitation sequence
ASRA starts epinephrine at less than 1 microgram/kg and advises avoiding vasopressin, beta blockers, calcium-channel blockers and additional local anesthetic. AHA considers bicarbonate reasonable for life-threatening wide-complex tachycardia and extracorporeal life support for refractory cardiogenic shock. These decisions accompany airway and circulatory support.
Continue care after the first response
ASRA continues lipid for more than 15 minutes after hemodynamic stability, within the cumulative limit. Its observation intervals are 2 hours after seizure and 4 to 6 hours after cardiovascular instability; post-arrest monitoring is individualized. Recurrent instability requires reassessment. Record exposure, doses, response and handoff instructions.
Quick check
Checking for saved practice…
Lesson
Block Toxic Metabolism and Preserve Oxygen Use
Toxic alcohols, cyanide, methemoglobin, and salicylates impair physiology through different chemistry. A gap, color, oxygen value, or concentration is meaningful only when connected to timing and the patient's condition.
- Toxic alcohols
- Fomepizole
- Cyanide
- Methemoglobinemia
- Salicylates
Block toxic metabolite formation with fomepizole; assess toxin-specific dialysis criteria.
Give hydroxocobalamin on high clinical suspicion with complete resuscitation.
Confirm the dyshemoglobin pattern and apply methylene-blue safety boundaries.
Stop toxic alcohol metabolism
Fomepizole competitively inhibits alcohol dehydrogenase and limits formation of toxic methanol and ethylene glycol metabolites. Severe acidosis, visual or kidney injury, very high concentrations, or clinical deterioration can require hemodialysis. Osmolar and anion gaps change across the course and cannot exclude exposure alone.
Treat suspected cyanide without delay
Cyanide blocks cellular oxygen utilization and can cause coma, shock, cardiovascular collapse, and severe lactic acidosis, especially after enclosed-space fire exposure. Current hydroxocobalamin labeling directs immediate use when clinical suspicion is high together with oxygen and airway, ventilatory, circulatory, and seizure support.
Prepare hydroxocobalamin for adult rescue
The CYANOKIT label starts adults at 5 g IV over 15 minutes; persistent severity may justify another 5 g, infused over 15 minutes to 2 hours according to condition, for 10 g total. Reconstitute the 5-g vial with 200 mL of normal saline; lactated Ringer solution or D5W may be used if saline is unavailable. Rock or invert for at least 60 seconds without shaking. Inspect for particles and the expected dark-red solution. At 25 mg/mL, 5,000 mg requires 200 mL. Use the prescribed infusion duration rather than confusing grams with milligrams.
Keep antidote infusions separate
Hydroxocobalamin needs a separate IV line. Sodium nitrite and sodium thiosulfate are incompatible with it in solution; a clinical decision to use more than one antidote does not permit mixing them or simultaneous administration through the same line. Reconstituted CYANOKIT must be used within 6 hours at no more than 40 degrees C and must not be frozen.
Account for carbon monoxide in smoke exposure
AHA 2025 recommends hydroxocobalamin for life-threatening cyanide poisoning in adults and children. If it is unavailable, nitrite plus thiosulfate is the recommended alternative for cyanide poisoning. With concurrent carbon monoxide toxicity, thiosulfate alone is reasonable instead: nitrite-induced methemoglobin further reduces oxygen carriage. Adding thiosulfate to hydroxocobalamin may be reasonable, but is not obligatory and has no comparative human trial establishing added benefit. Not every smoke exposure establishes cyanide poisoning; integrate exposure and clinical severity while providing resuscitation.
Calculate pediatric hydroxocobalamin with the adult cap
AHA 2025 lists an initial hydroxocobalamin dose of 70 mg/kg for children, capped at the adult initial dose of 5 g. This is guideline-supported rescue; the US CYANOKIT label still states pediatric safety and effectiveness have not been established. At 25 mg/mL, a 20-kg child requires 1,400 mg, or 56 mL, for this initial dose. Coordinate preparation, infusion and any repeat with toxicology and pediatric pharmacy.
Stop nitroprusside when cyanide toxicity is suspected
Nitroprusside generates cyanide during metabolism. Hepatic dysfunction increases susceptibility, and a rising infusion requirement can precede metabolic acidosis. Do not wait for acidosis or a confirmatory cyanide level before stopping the infusion and arranging urgent antidote and resuscitative care when toxicity is suspected. Follow the current AHA hydroxocobalamin pathway above; a historical nitroprusside label listing nitrite and thiosulfate is not evidence that hydroxocobalamin is inappropriate.
Distinguish thiocyanate accumulation
Cyanide detoxification produces thiocyanate, whose elimination depends on the kidneys. Prolonged nitroprusside exposure and renal impairment increase accumulation risk; tinnitus, miosis and hyperreflexia may signal neurotoxicity. Severe thiocyanate toxicity can require hemodialysis. Dialysis does not effectively remove cyanide itself and cannot replace prompt cyanide antidote treatment. Follow clinical findings, exposure and the relevant toxin concentration rather than treating cyanide and thiocyanate as interchangeable laboratory results.
Apply product-specific renal infusion limits
The ready-to-use nitroprusside label limits the mean rate to less than 3 mcg/kg/min when eGFR is below 30 mL/min/1.73 m2, and to 1 mcg/kg/min in anuria. Continuous blood-pressure monitoring remains necessary. These limits do not guarantee freedom from toxicity. The same label recommends thiocyanate surveillance even with normal renal function when cumulative exposure exceeds 7 mg/kg/day. Record rate, duration and cumulative dose; an infusion rate in mcg/kg/min is not a cumulative amount in mg/kg.
Calculate the two NITHIODOTE components separately
When nitrite plus thiosulfate is selected, the December 2024 US label gives adult sodium nitrite 300 mg (10 mL of 30 mg/mL) IV at 2.5 to 5 mL/min, followed immediately by sodium thiosulfate 12.5 g (50 mL of 250 mg/mL). Pediatric doses are nitrite 6 mg/kg (0.2 mL/kg), maximum 300 mg, at the labeled 2.5 to 5 mL/min rate, then thiosulfate 250 mg/kg (1 mL/kg), maximum 12.5 g. These are different concentrations and volumes. For a 20-kg child before patient-specific adjustment, calculate nitrite 120 mg in 4 mL and thiosulfate 5 g in 20 mL. Monitor blood pressure and reduce infusion rates if significant hypotension develops.
Adjust nitrite to oxygen-carrying reserve
Anemia calls for a proportional reduction of nitrite according to hemoglobin and oxygen-carrying capacity, with toxicology guidance. Do not automatically give an entire adult vial to a child. Infants, especially under 6 months, have greater methemoglobinemia susceptibility. Consider alternatives in G6PD deficiency because nitrite can cause hemolysis. Renal dysfunction increases the risk of toxicity from these renally excreted antidotes. These cautions reinforce the hydroxocobalamin preference and the separate carbon-monoxide pathway above.
Follow response rather than a methemoglobin target
NITHIODOTE labeling directs monitoring for 24 to 48 hours for perfusion, oxygenation and recurrent cyanide toxicity. Obtain hemoglobin when feasible and measure methemoglobin with co-oximetry; ordinary pulse oximetry or a saturation calculated from arterial oxygen tension is unreliable. Do not administer nitrite merely to create a chosen methemoglobin percentage. Keep methemoglobin below 30% and stop nitrite if it exceeds 30%. If poisoning recurs, the labeled repeat is half the original dose of each component, guided by clinical response and safety reassessment. Nitrite and thiosulfate may run sequentially through the same line; neither should share simultaneous administration with hydroxocobalamin.
Warn the laboratory and dialysis team
Hydroxocobalamin changes sample color and can distort chemistry, coagulation and urine measurements; direction and duration depend on the assay, instrument and dose. A post-treatment creatinine or INR requires laboratory context, not automatic acceptance or dismissal. The dye can also trigger a false blood-leak alarm on some dialysis machines. Alert nephrology and the dialysis team before treatment is needed so necessary kidney support can be arranged safely. A pretreatment cyanide specimen may help documentation if collection does not delay rescue.
Continue safety monitoring after rescue
Monitor blood pressure and hypersensitivity during administration, and renal function for 7 days after CYANOKIT. Red urine is expected but does not rule out real kidney injury. Life-saving treatment should not be withheld in pregnancy. The US label has not established pediatric safety and effectiveness, although AHA recommends pediatric rescue based largely on adult evidence; use a specialist pediatric dosing protocol. Breastfeeding is not recommended during treatment, and the label does not establish a safe restart interval.
Recognize dyshemoglobinemia
Acquired methemoglobinemia can cause cyanosis, a saturation gap, chocolate-colored blood, and tissue hypoxia despite adequate arterial oxygen tension. Methylene blue is used for clinically significant disease, but G6PD-related hemolysis risk, serotonergic drug interactions, kidney function, and monitoring interference require attention.
Recognize delayed mushroom hepatotoxicity
Amatoxins inhibit RNA polymerase II and can cause liver-cell death. Vomiting or diarrhea beginning after, or persisting beyond, 6 hours after wild mushrooms is concerning; early symptoms do not exclude a mixed-species meal. Cooking does not reliably detoxify amatoxins. Obtain urgent poison-center assessment and serial liver, coagulation, kidney and metabolic testing; initial laboratory results can be normal.
Do not substitute atropine for hepatic rescue
The amatoxin pathway is different from muscarinic mushroom poisoning. Atropine treats dangerous muscarinic effects, not amatoxin-induced liver failure. Suspected amatoxin poisoning needs supportive care, fluid and electrolyte correction and early specialist management, including transplant evaluation when severe. As described by CDC in 2026, no FDA-approved amatoxin therapy exists. Acetylcysteine and penicillin G are used off-label with uncertain benefit; silibinin access requires an emergency investigational pathway coordinated by specialists. Do not portray these therapies as proven cures.
Keep salicylate patients alkalemic
Salicylates can produce tinnitus, vomiting, tachypnea, fever, confusion, pulmonary edema, and a mixed respiratory alkalosis and metabolic acidosis. Give bicarbonate to alkalinize serum and urine, correct potassium, avoid preventable acidemia, and mobilize hemodialysis early for severe clinical toxicity. Chronic poisoning can be dangerous at lower concentrations than acute poisoning.
Quick check
Checking for saved practice…
Lesson
Block Toxic Alcohol Metabolism and Coordinate Removal
Keep toxin identity, antidote timing and metabolic injury together when choosing rescue.
- Fomepizole
- Dialysis transitions
- Methanol
- Ethylene glycol
- Gap formulas
Track each dose and reconcile the schedule when dialysis starts or stops.
Use the right concentration units, gap formula and clinical indications.
Metabolic recovery, kidney support and antidote completion require distinct decisions.
Treat suspected toxic metabolism promptly
Fomepizole blocks alcohol dehydrogenase. Begin treatment when methanol or ethylene glycol poisoning is strongly suspected rather than waiting for a send-out level. Follow exposure timing, ethanol coexposure, mental status, vision, renal function, electrolytes, pH and serial concentrations. A normal late osmolar gap does not exclude metabolite injury.
Keep the antidote schedule visible
The labeled regimen is 15 mg/kg IV initially, then 10 mg/kg every 12 hours for four doses, then 15 mg/kg every 12 hours. Dilute in at least 100 mL of normal saline or D5W and infuse over 30 minutes; never give the concentrate as a bolus. The reviewed 1-g/mL product prohibits polycarbonate syringes and needles. A 70-kg loading dose is 1,050 mg, requiring 1.05 mL of concentrate before dilution.
Reconcile doses at dialysis transitions
The label changes fomepizole to every 4 hours during hemodialysis. At initiation, give the next scheduled dose if at least 6 hours have elapsed; otherwise do not add a starting dose. At completion, time since the last dose determines the supplement: less than 1 hour, none; 1 to 3 hours, half the next dose; over 3 hours, the full next dose. Resume the 12-hour schedule from the last administered dose. Verify a separate protocol for continuous kidney replacement.
Use methanol-specific escalation criteria
EXTRIP recommends extracorporeal treatment for coma, seizures, new visual deficits, pH at or below 7.15, persistent acidosis despite treatment, anion gap above 24 mmol/L calculated as Na - Cl - bicarbonate, or impaired kidney function. Concentration triggers depend on blockade: above 70 mg/dL with fomepizole, 60 mg/dL with ethanol, or 50 mg/dL without an inhibitor. Any criterion can trigger escalation. Continue alcohol-dehydrogenase inhibition and folate during treatment.
Separate ethylene glycol from methanol
EXTRIP suggests dialysis for ethylene glycol above 310 mg/dL with fomepizole. With ethanol, it recommends treatment above 310 mg/dL and suggests it at 124 to 310 mg/dL; without an antidote, it recommends treatment above 62 mg/dL. These concentration criteria do not override clinical severity. Coma, seizures or KDIGO stage 2 or 3 acute kidney injury independently support treatment; chronic kidney disease with eGFR below 45 mL/min/1.73 m² supports consideration.
Use the correct anion-gap formula
For suspected ethylene glycol exposure, EXTRIP uses Na + K - Cl - bicarbonate: treatment is recommended above 27 mmol/L and suggested at 23 to 27 mmol/L. This differs from its methanol formula. With Na 140, K 4, Cl 106 and bicarbonate 12 mmol/L, the ethylene-glycol gap is 26, not 22. Glycolate above 12 mmol/L supports treatment; 8 to 12 supports consideration. An elevated gap without evidence of exposure is not itself proof of poisoning.
Recognize the evidence and labeling difference
The fomepizole label advises considering dialysis at either alcohol concentration of at least 50 mg/dL, renal failure or important acidosis. EXTRIP uses toxin-specific criteria that account for antidote availability, metabolic injury and clinical findings. Do not flatten these into one universal cutoff or interpret a higher EXTRIP concentration threshold as permission to defer dialysis in a deteriorating patient. Its recommendations rely on very low-quality evidence and require specialist interpretation.
Separate dialysis recovery from antidote completion
Intermittent hemodialysis is preferred. For methanol, EXTRIP pairs clinical improvement with a level below 20 mg/dL before cessation. For ethylene glycol, it recommends an anion gap including potassium below 18 mmol/L and suggests a level below 25 mg/dL with correction of acid-base abnormalities; sustained metabolic recovery matters. Persistent renal injury may still require kidney support. Fomepizole has separate labeled stopping criteria: undetectable or below 20 mg/dL, no symptoms and normal pH.
Avoid ineffective charcoal treatment
The 2026 consensus recommends against single, additional and multiple-dose activated charcoal for toxic alcohol ingestion. Poor adsorption means charcoal does not substitute for metabolic blockade, correction of derangements or indicated extracorporeal removal. A coingested charcoal-adsorbable drug requires its own risk assessment.
Distinguish isolated isopropanol exposure
Isopropanol can cause marked sedation, respiratory depression, hypotension and gastrointestinal irritation or bleeding. Conversion to acetone commonly produces ketosis without the high-gap acidosis expected from methanol or ethylene glycol. Investigate acidosis for shock, coexposures or another cause rather than forcing every alcohol exposure into one pattern. A product history and confirmatory testing remain important.
Avoid prolonging isopropanol toxicity
For confirmed isolated isopropanol poisoning, provide airway, breathing and circulatory support; do not routinely administer fomepizole or ethanol. Blocking alcohol dehydrogenase delays clearance of the parent intoxicant. Severe cases may require expert-directed dialysis, but most do not. Suspected mixed ingestion requires toxicologist-guided decisions; the isolated-isopropanol rule must not delay treatment for possible methanol or ethylene glycol.
Recognize diethylene glycol beyond antifreeze
Diethylene glycol can contaminate liquid medicines and cause severe acute kidney injury. A cluster of unexplained oliguria or anuria after a shared syrup exposure should trigger urgent toxicology and public-health investigation. Stop use of the suspected product, preserve the bottle and lot information for testing, and evaluate acid-base status, renal function and organ support needs. An apparently ordinary medicine name does not establish that its ingredients are safe.
State the limits of diethylene-glycol rescue evidence
Fomepizole has been used off-label with kidney replacement therapy for suspected or confirmed diethylene-glycol poisoning. Animal experiments support blocking toxic metabolite formation, and human reports describe treatment, but comparative clinical evidence is limited. A 2025 retrospective series combined suspected or confirmed ethylene- and diethylene-glycol cases, with all children receiving fomepizole and many receiving continuous kidney replacement. It cannot isolate the antidote’s causal benefit. Seek early specialist-directed treatment without importing ethylene-glycol numerical thresholds as validated diethylene-glycol rules.
Interpret surrogate measurements cautiously
EXTRIP ethylene-glycol osmol-gap triggers require evidence of exposure and adjustment for ethanol. With fomepizole, a gap above 50 supports consideration; with ethanol it recommends treatment above 50 and suggests it at 20 to 50; without an antidote, above 10 supports treatment. These are treatment-context criteria, not a diagnostic screening rule. Kidney injury and ketoacidosis can raise the anion gap independently, while hypoalbuminemia can conceal part of it.
Quick check
Checking for saved practice…
Lesson
Follow Salicylate Physiology Through Rescue
Interpret concentration, acid-base status and organ injury together before choosing elimination therapy.
- Serial levels
- Ventilation
- Urine pH
- Potassium
- Hemodialysis
A lower reported level does not cancel worsening organ injury.
Track separate targets and potassium during alkalinization.
Escalate on clinical criteria as well as concentration.
Read the trajectory with the concentration
Reconstruct acute versus repeated exposure, formulation and all salicylate sources, including bismuth subsalicylate and methyl salicylate. Follow serial concentrations with pH and symptoms. The Done nomogram is unreliable. A falling blood concentration with worsening confusion or acidemia can reflect increasing tissue toxicity rather than recovery.
Protect compensatory ventilation
Respiratory alkalosis and metabolic acidosis can coexist despite a near-normal pH. Hyperventilation alone does not require intubation. If airway failure makes intubation necessary, involve experienced critical care staff, minimize apnea and preserve the compensatory minute ventilation; monitor blood gases closely. Sedation-related CO2 retention can rapidly worsen toxicity.
Distinguish blood from urine targets
The Utah April 2025 protocol targets blood pH 7.50 to 7.55, urine pH 7.5 to 8.0 and potassium 4.0 to 4.5 mEq/L. Bicarbonate can be appropriate despite mild blood alkalemia because urine may remain acidic. Correct volume depletion and hypokalemia while checking renal function, fluid tolerance and serial electrolytes. Do not give potassium automatically to a patient who cannot safely excrete it.
Calculate the prescribed infusion
The Utah adult pathway uses an initial 1 mEq/kg IV bicarbonate dose followed by an infusion commonly containing 150 mEq bicarbonate and 40 mEq potassium chloride in D5W at 200 to 250 mL/hour. This is an attributed starting pathway, not a fixed order for every patient. If pharmacy specifies a final volume of 1,000 mL and the ordered rate is 200 mL/hour, delivery is 30 mEq bicarbonate/hour and 8 mEq potassium/hour. Verify final volume and actual ampule concentration.
Use independent dialysis triggers
EXTRIP recommends extracorporeal treatment for salicylate above 100 mg/dL, above 90 mg/dL with impaired kidney function, altered mental status, new hypoxemia needing supplemental oxygen, or failed standard treatment. It suggests treatment above 90 mg/dL, above 80 mg/dL with impaired kidney function, or systemic pH at or below 7.20. Any one criterion can apply; these are not combined requirements. Evidence quality is very low.
Reassess through dialysis and recovery
EXTRIP prefers intermittent hemodialysis and advises IV bicarbonate between sessions. Its stopping criteria require clinical improvement together with a concentration below 19 mg/dL. When concentrations are unavailable, at least 4 to 6 hours of treatment substitutes for the concentration criterion; clinical improvement is still required. Continue reassessment for ongoing absorption and recurrence. A value of 450 mg/L equals 45 mg/dL; always reconcile units before applying a threshold. Severe chronic toxicity can need dialysis at concentrations below acute numerical triggers.
Match charcoal to the formulation
At an ingested dose threshold of 200 mg/kg, the 2026 consensus recommends single-dose charcoal through 2 hours for immediate-release salicylates and 3 hours for modified-release products; it suggests use through 4 and 5 hours, respectively. Later use requires individualized assessment, with immediate-release use beyond 6 hours discouraged. Additional-dose thresholds are 500 mg/kg for immediate-release and 350 mg/kg for modified-release. Multiple-dose elimination therapy remains individualized. Charcoal must not delay resuscitation or dialysis and requires airway and bowel safeguards.
Follow physiology after the number improves
Assess neurologic status, oxygenation, glucose, renal function, electrolytes and acid-base recovery together. Brain glucose availability may be inadequate even when peripheral glucose is normal, so altered mental status warrants consideration of dextrose during expert-directed rescue. Neither one reassuring level nor a normal calculated anion gap excludes important toxicity; laboratory chloride interference can obscure the gap.
Quick check
Checking for saved practice…
Lesson
Restore Oxygen Carriage Without Adding Oxidant Harm
Separate a normal oxygen tension from effective hemoglobin oxygen carriage, then select and monitor antidotal treatment without overlooking renal function, G6PD deficiency or serotonin interactions.
- Co-oximetry
- Methylene blue
- G6PD
- Renal dosing
- Serotonin risk
A normal oxygen tension can coexist with impaired hemoglobin oxygen delivery.
Check G6PD, kidney function, interactions and the actual drug concentration.
Follow clinical recovery and measured methemoglobin; escalate failed or contraindicated therapy.
Identify impaired oxygen carriage
Oxidation of hemoglobin iron from Fe2+ to Fe3+ impairs oxygen delivery. Dapsone, benzocaine and nitrites are important exposures. Cyanosis, dark blood and hypoxic symptoms despite an apparently adequate arterial oxygen tension suggest a dyshemoglobin problem. Stop the oxidant exposure, provide oxygen and support airway and circulation; a normal oxygen tension does not establish normal oxygen carriage.
Measure the right signal
Obtain blood co-oximetry to measure methemoglobin and follow the clinical trajectory. Conventional pulse oximetry and a calculated blood-gas saturation cannot quantify the dyshemoglobin burden. Symptom severity also depends on anemia and cardiopulmonary reserve. Do not wait for a fixed percentage in a deteriorating patient; AHA recommends methylene blue for life-threatening methemoglobinemia while contraindications and rescue alternatives are assessed.
Use the labeled product regimen deliberately
For acquired methemoglobinemia in adults and children, PROVAYBLUE is labeled at 1 mg/kg IV over 5-30 minutes. A repeat dose up to 1 mg/kg may be given after one hour if methemoglobin remains above 30% or symptoms persist. That repeat-dose threshold is not a universal threshold for starting treatment. After failure of two doses, consider alternative interventions. AHA lists a broader methylene-blue dose range; do not silently combine its table with this product-specific repeat schedule.
Calculate the volume before choosing the pump setting
PROVAYBLUE contains 5 mg/mL. A prescribed 1 mg/kg dose for a 60-kg patient is 60 mg, or 12 mL of drug solution. If pharmacy prepares that dose to a specified final volume of 60 mL and it is ordered over 20 minutes, the pump rate is 180 mL/h. The 12-mL withdrawal and 60-mL final volume are different quantities. The label permits dilution in 50 mL D5W, advises against sodium-chloride diluents, and calls for immediate use after dilution. Use patent IV access, not subcutaneous administration; verify the final preparation rather than assuming every methylene-blue product is 10 mg/mL.
Apply the renal and G6PD boundaries
For eGFR 15-59 mL/min/1.73 m2, the PROVAYBLUE label specifies a single 1 mg/kg dose; persistent symptoms or methemoglobin above 30% at one hour prompt alternative interventions. Do not automatically apply the routine repeat dose. G6PD deficiency is a labeled contraindication because the drug can be ineffective and cause severe hemolysis. Severe thiazine-dye hypersensitivity is also a contraindication. Obtain expert help for alternative rescue rather than treating G6PD deficiency as a reason to increase the dose.
Review serotonergic exposure before administration
Methylene blue inhibits monoamine oxidase and can precipitate serious or fatal serotonin syndrome with serotonergic medicines, including antidepressants, opioids and dextromethorphan. The label advises avoiding concomitant use. If urgent IV use cannot be avoided, it specifies the lowest possible dose and close CNS observation for up to four hours; this is an expert risk-benefit decision alongside resuscitation. Monitor for clonus, hyperreflexia, agitation, hyperthermia and autonomic instability. Counsel against serotonergic drugs for 72 hours after the last dose, with medication resumption coordinated clinically.
Consider dapsone elimination separately
The 2026 consensus recommends multiple-dose charcoal for dapsone ingestion at a 10-mg/kg threshold, with very low-quality evidence. Apply airway and bowel safeguards with toxicology. Removing dapsone does not replace treatment of methemoglobinemia or monitoring for recurrence and hemolysis.
Watch for rebound, hemolysis and measurement interference
Dapsone or aniline exposure can cause recurrence after initial improvement. Follow methemoglobin, symptoms and hemolysis through resolution rather than treating initial color improvement as cure. Anemia can be delayed a day or more; severe hemolysis requires stopping methylene blue and alternative care. The dye itself can lower pulse-oximeter readings, so an isolated post-dose decline does not prove worsening hypoxia. Hepatic impairment warrants longer monitoring; the label also advises interrupting breastfeeding during and for up to eight days after treatment.
Escalate when methylene blue cannot solve the problem
AHA states that exchange transfusion or hyperbaric oxygen may be reasonable for life-threatening disease unresponsive to methylene blue, with limited evidence and availability constraints. Ascorbic acid may be considered when methylene blue is contraindicated or unavailable, but it acts slowly and is not a reliable sole resuscitation measure. Acetylcysteine is not recommended for life-threatening adult methemoglobinemia. Continue oxygen and circulatory support while specialist rescue is arranged.
Identify the mothball ingredient
Mothballs may contain naphthalene or paradichlorobenzene. Recover the label instead of treating the product name as a chemical identification. Swallowing is not the only route: vapors and contaminated clothing can also expose a child. Contact Poison Control promptly after suspected ingestion, even if the child initially appears well.
Separate red-cell destruction from oxidation
Naphthalene exposure can cause hemolytic anemia and kidney injury; methemoglobinemia is a separate possible complication. G6PD deficiency increases susceptibility to hemolysis, but its absence does not exclude injury, especially in infants. Falling hemoglobin, jaundice or dark urine after exposure warrants urgent reassessment. Assess anemia and renal injury alongside co-oximetry when impaired oxygen carriage is suspected.
Treat the complication rather than the product name
Methylene blue treats acquired methemoglobinemia; it is not a general antidote for mothball ingestion or a treatment for hemolytic anemia itself. PROVAYBLUE is contraindicated in G6PD deficiency and can worsen hemolysis. Support oxygenation and circulation, stop ongoing exposure and involve toxicology; severe anemia may require transfusion. If methemoglobinemia is present, use the contraindication and alternative-rescue pathway above rather than automatically giving the dye.
Plan follow-up and remove the source
Solid naphthalene can dissolve slowly, prolonging absorption. A reassuring first examination does not establish that subsequent blood or kidney injury is excluded. Arrange reassessment appropriate to the exposure and clinical course. Paradichlorobenzene has a different toxicity profile but large or chronic exposure can also injure red cells and the nervous system. Wash stored clothes and bedding before use, follow pesticide-label directions and keep mothballs inaccessible to children.
Prevent the next benzocaine exposure
FDA advises against benzocaine for teething pain in children, and oral benzocaine products should not be used below age two. A brand name alone does not establish its ingredients. For ordinary teething discomfort, FDA describes gentle gum massage with a clean finger or a firm rubber teething ring; an ill or cyanotic child needs urgent assessment.
Quick check
Checking for saved practice…
Lesson
Protect the Lungs After a Hydrocarbon Exposure
Connect route and respiratory findings to first aid, observation and supportive treatment.
- Aspiration
- Chemical pneumonitis
- Product identity
- Observation
Recover the product history without delaying respiratory assessment.
Avoid induced vomiting and evaluate possible aspiration.
Initial improvement alone does not establish sustained recovery.
Identify the product and route
Gasoline, kerosene, lighter fluid and some oils or solvents can injure the lungs when aspirated. Obtain the container and ingredients, amount, timing, route and coexposures. Inhaled vapor can also cause neurologic toxicity. A generic product category does not establish the toxicity of every ingredient.
Do not turn ingestion into aspiration
Do not induce vomiting after petroleum hydrocarbon ingestion. Avoid gastric lavage and activated charcoal for isolated gasoline exposure. These measures can add aspiration risk without useful benefit. Do not force food or drinks into a coughing, vomiting or drowsy patient; seek poison-center guidance rather than attempting home gastrointestinal decontamination.
Recognize evolving lung injury
Coughing or choking after ingestion raises concern for aspiration. Wheezing, rapid breathing, hypoxemia or respiratory distress require evaluation; deterioration can follow an initially reassuring appearance. Assess oxygenation and obtain chest imaging when respiratory findings warrant it. Fever after aspiration does not by itself establish bacterial pneumonia.
Support the injured system
There is no specific antidote for gasoline. Provide oxygen and respiratory support as needed; bronchospasm may require a bronchodilator. Chemical pneumonitis does not routinely require corticosteroids or prophylactic antibiotics. Treat documented bacterial infection when present. Significant exposure also warrants attention to consciousness, seizures, electrolytes and cardiac rhythm.
Recognize volatile-associated cardiac collapse
Volatile hydrocarbon exposure can cause lethal ventricular arrhythmias as well as lung injury. Correct hypoxia and electrolyte abnormalities while providing standard resuscitation and urgent toxicology support; fluorinated products may cause hypocalcemia. AHA 2025 states that beta-adrenergic antagonists may be reasonable for ventricular arrhythmias refractory to standard treatment in adults and children. This weak recommendation rests on expert opinion and limited reports; it does not make beta blockade routine after every fuel exposure or replace defibrillation and respiratory support.
Observe before declaring recovery
The Royal Children's Hospital pediatric guideline uses six hours of observation after exposure for asymptomatic children with normal vital signs; respiratory or neurologic symptoms warrant longer observation and care. Discharge requires clinical recovery and clear return precautions. This is an institutional pediatric pathway, not a universal home-observation instruction for every product or exposure.
Stop continued exposure
Move away from fumes only when this can be done safely; unprotected rescuers should not enter a contaminated confined space. Remove fuel-soaked clothing and wash exposed skin with soap and water. Irrigate exposed eyes promptly. Prevent recurrence by keeping fuels in their original labeled containers, away from children, and never siphoning by mouth.
Quick check
Checking for saved practice…
Lesson
Recognize Nicotine Toxicity Across Products and Phases
Trace the exposure, recognize changing autonomic and respiratory findings, and provide support without mistaking early improvement for recovery.
- Nicotine receptors
- Biphasic toxicity
- Liquid concentration
- Skin exposure
- Supportive care
Liquid, tobacco and therapeutic products contribute to the exposure history.
Do not require a witnessed early phase before recognizing severe toxicity.
Treat the failing system and follow the clinical course.
Reconstruct the exposure without delaying help
Nicotine can be absorbed through ingestion, inhalation, skin and mucous membranes. Identify liquids, tobacco, pouches and therapeutic products, including concurrent sources. FDA advises immediately calling Poison Control after e-liquid ingestion at any age or possible exposure in a child, even when uncertain. Severe symptoms require emergency services.
Follow stimulation into depression
Nicotine initially stimulates and, with substantial exposure, can block nicotinic receptors. Early vomiting, sweating, agitation and tachycardia may progress to bradycardia, hypotension, weakness, hypoventilation or coma. Seizures can occur. The phases are not obligatory: some patients present with depression without a witnessed stimulatory interval.
Estimate contained dose without inventing a safe threshold
For a stated 20 mg/mL solution and a credible 0.5-mL ingestion, the product contains an estimated 10 mg nicotine. In a 10-kg child, that is 1 mg/kg of estimated swallowed nicotine. This is not a measured absorbed dose or a discharge threshold. Uncertain concentration or volume must remain explicit; the calculation must not delay assessment.
Remove contamination and support physiology
Wash contaminated skin with soap and water and irrigate exposed eyes. Remove ongoing exposure safely; do not induce vomiting. Support breathing and circulation, monitor rhythm, and treat seizures with benzodiazepines. Atropine may treat clinically important bradycardia or secretions, but it does not replace ventilation for neuromuscular respiratory failure.
Keep charcoal exceptional
The Royal Children's Hospital nicotine guideline describes charcoal as very rarely indicated, reserved for selected early high-risk exposures after toxicologist discussion. It is not home first aid. Vomiting and impaired consciousness make airway safety central; do not turn historical suggestions for repeated charcoal into an automatic treatment course.
Base disposition on the course
That pediatric guideline monitors asymptomatic patients or those recovering from gastrointestinal symptoms alone for four hours before discharge, with normal consciousness and ECG. This does not authorize discharging a patient with persistent cardiopulmonary or neurologic toxicity. Significant exposures, resuscitation needs and intentional poisoning require further care and a safety assessment.
Prevent access after the event
Keep e-liquids in their original containers with caps secured and stored out of sight and reach of children and pets. Include visitors' bags and coats in the storage plan. Clean spills promptly. A food-like flavor or package does not make the contents safe to swallow.
Quick check
Checking for saved practice…
Lesson
Separate Wet, Dry, Adrenergic, and Serotonergic Emergencies
Autonomic and neuromuscular findings can rapidly distinguish several dangerous syndromes. The treatment target is the physiology that threatens the airway, brain, temperature, and circulation.
- Organophosphates
- Atropine
- Pralidoxime
- Anticholinergic
- Sympathomimetic and serotonin
Dry secretions with atropine and reverse appropriate organophosphate enzyme inhibition with pralidoxime.
Separate anticholinergic dryness from sympathomimetic sweating, then control heat and agitation.
Use hyperreflexia and clonus to distinguish serotonin toxicity from a medication list alone.
Treat the cholinergic airway
Organophosphate acetylcholinesterase inhibition produces bronchorrhea, bronchospasm, salivation, vomiting, diarrhea, urination, bradycardia or tachycardia, fasciculations, weakness, and respiratory paralysis. Protect staff from contamination. Titrate atropine to improved bronchial secretions and ventilation, not pupil size, and give pralidoxime early for appropriate exposures.
Treat muscarinic and nicotinic failure together
Atropine reduces bronchorrhea, bronchospasm and other muscarinic effects, but cannot reverse nicotinic respiratory muscle paralysis. AHA 2025 recommends immediate atropine and early intubation for life-threatening organophosphate or carbamate poisoning. Provide oxygen, suction and ventilatory support concurrently. Benzodiazepines treat seizures and agitation. Avoid succinylcholine and mivacurium because cholinesterase inhibition can markedly prolong their blockade; select an alternative neuromuscular blocker with the airway team.
Escalate atropine against the airway findings
The AHA initial atropine doses are 1 to 2 mg IV in adults and 0.02 mg/kg in children, doubled every 5 minutes until muscarinic toxicity is controlled. Assess chest secretions, bronchospasm, ventilation and perfusion together; persistent miosis alone does not justify escalation. Poisoning may require doses far beyond routine bradycardia treatment. Continue expert-titrated maintenance and reassess for recurrent secretions as well as antimuscarinic toxicity; a dry mouth alone does not prove that the lungs are clear.
Calculate maintenance from the total atropinizing dose
The US atropine poisoning tables and Australian national chemical-exposure guidance use an initial maintenance infusion of 10% to 20% of the total loading dose required for response per hour, then titrate to pulmonary findings and perfusion. If sequential boluses of 2, 4, 8 and 16 mg establish control, the total is 30 mg, so that approach starts at 3 to 6 mg/hour, not 10% to 20% of the last 16-mg bolus alone.
Keep conflicting atropine protocols explicit
The AHA 2025 summary table also prints an adult 2-mg/hour cap; this conflicts with these response-based regimens. The worked example follows the label and response-based protocol, not the AHA table cap. Austin toxicology guidance likewise starts at 10% to 20% of the cumulative loading dose per hour and titrates to effect; its observation that rates above 3 to 5 mg/hour are uncommon is not an absolute maximum. Obtain poison-center direction for the actual patient and monitor closely when substantial doses remain necessary. Monitor for recurrent bronchorrhea, bronchospasm and hypoperfusion as well as delirium, hyperthermia and other atropine toxicity. Ischemic heart disease warrants particular monitoring and an individualized risk-benefit decision.
Watch for respiratory weakness after initial improvement
Drying secretions does not end monitoring. Some organophosphate exposures cause an intermediate syndrome with delayed neuromuscular weakness and respiratory paralysis, described in Australian guidance around 2 to 4 days after exposure. Reassess strength and ventilation even if the initial cholinergic crisis has improved. A later peripheral neuropathy can develop over subsequent weeks with certain agents. Observation and follow-up depend on the agent, exposure course and clinical recovery; a single normal examination or elapsed antidote interval is not a universal discharge rule.
Protect rescuers while stopping absorption
Use exposure-appropriate PPE and prevent contamination of staff and the treatment area. For external pesticide contamination, remove contaminated clothing and wash with copious soap and water while resuscitation proceeds. AHA 2025 supports this approach. Do not substitute an older label instruction to wash skin with alcohol. Obtain product identification and involve the poison center without delaying airway care or atropine.
Distinguish unknown poison from confirmed carbamate
Pralidoxime can reactivate organophosphate-inhibited acetylcholinesterase before aging makes reactivation ineffective; benefit depends on the agent and timing. AHA considers it reasonable in life-threatening organophosphate poisoning and says it should not be withheld solely because the cholinesterase poison class is unknown. For confirmed carbamate poisoning, AHA finds evidence insufficient for or against oximes; PROTOPAM labeling specifically warns against carbamate-pesticide use because carbaryl toxicity may increase. Do not generalize the unknown-exposure recommendation into routine treatment of known carbaryl poisoning. Use toxicology guidance.
Separate pralidoxime preparation from the delivered dose
For adult IV treatment, PROTOPAM labeling gives 1 to 2 g over 15 to 30 minutes. Reconstitute each 1-g vial with 20 mL sterile water to 50 mg/mL, then dilute with normal saline to 10 to 20 mg/mL for infusion. Rapid administration can worsen neuromuscular and cardiovascular findings; the label limits intermittent administration to 200 mg/min. For a prescribed 2-g dose in a final 100 mL over 30 minutes, the pump rate is 200 mL/hour and delivery is about 67 mg/min. This example does not set the repeat or maintenance regimen. Pediatric loading is 20 to 50 mg/kg, maximum 2 g, over 15 to 30 minutes; the labeled continuous option is 10 to 20 mg/kg/hour. Renal insufficiency requires dose reduction and individualized toxicology/pharmacy review.
Use DuoDote within its device-specific indication
DuoDote provides fixed IM doses of atropine 2.1 mg and pralidoxime chloride 600 mg per single-use device. Its prescribing information covers symptomatic organophosphorus insecticide or nerve-agent poisoning in adults and children weighing more than 41 kg. Safety and effectiveness at 41 kg or below are not established; use a weight-appropriate specialist treatment pathway instead of assuming this fixed device is suitable. It is intended for trained healthcare providers and initial rescue, with immediate definitive medical care.
Match the number of devices to symptom severity
For known or suspected exposure with at least two mild symptoms, the DuoDote label directs one injection. If any severe symptom develops afterward, give two additional devices promptly. Severe symptoms at presentation call for three devices in rapid succession; examples include confusion, major respiratory difficulty, copious airway secretions, convulsions or unconsciousness. Three devices deliver a total of 6.3 mg atropine and 1,800 mg pralidoxime chloride. After the initial mild-symptom dose, reassess over 10 to 15 minutes; without development of severe symptoms, the label does not recommend additional DuoDote injections. Persistent symptoms still need medical reassessment, and this device sequence does not cap all subsequent hospital antidote therapy.
Keep the device technique and handoff explicit
Inject DuoDote into the mid-lateral thigh. Keep fingers away from the green needle end, remove the gray safety release only when ready, and press the green end perpendicular to the thigh until activation, holding it in place for about 10 seconds. Clothing is permitted, but empty the pocket over the injection site. Follow the manufacturer instructions for handling the exposed needle and preserve the dose count for the receiving team. Continue safe evacuation, decontamination and respiratory support; the label calls for close supervision for at least 48 to 72 hours. Initial improvement is not clearance for discharge.
Recognize medication-induced cholinergic crisis
Excess pyridostigmine or neostigmine can worsen weakness through excessive acetylcholinesterase inhibition. In a patient with myasthenia gravis, weakness alone cannot distinguish undertreatment from toxicity. Reconstruct extra doses, formulation, timing, kidney function and co-medications; look for diarrhea, sweating, salivation, bronchial secretions, miosis and fasciculations. Suspected cholinergic crisis requires withholding the causative anticholinesterase and urgent respiratory assessment with neurology and toxicology. Do not automatically increase pyridostigmine because the patient is weaker.
Separate secretion control from reversal of weakness
Atropine treats dangerous muscarinic effects of medication overdose, but drying secretions does not demonstrate reversal of nicotinic muscle weakness. Muscarinic symptom suppression can mask excessive pyridostigmine exposure. Maintain airway and ventilatory support as needed. RxPrep lists pralidoxime for neostigmine/pyridostigmine overdose, and PROTOPAM labeling includes anticholinesterase-drug overdose; however, selection and dosing need specialist assessment rather than automatic transfer of a pesticide regimen or DuoDote device. PROTOPAM also cautions that it can precipitate myasthenic crisis in patients with MG. Keep the exposure-specific treatment decision distinct from routine neuromuscular-block reversal after anesthesia.
Identify antipsychotic toxicity by the actual findings
After antipsychotic overdose, support airway, ventilation and circulation and obtain ECG monitoring. Sedation, hypotension, antimuscarinic findings and movement disorders require different responses. A drug-class name does not select one antidote. Quetiapine labeling emphasizes supportive care and poison-center consultation; modified-release exposure may have delayed and prolonged effects.
Treat acute dystonia without treating every movement alike
New sustained jaw, neck or eye contractions after a dopamine-blocking drug suggest acute dystonia. Assess swallowing and breathing immediately when the head or neck is involved. The reviewed benztropine injection is 1 mg/mL for IM or IV use; its acute-dystonia dose of 1 to 2 mL supplies 1 to 2 mg. Verify the patient, product and syndrome before administration.
Respect benztropine limits
Benztropine is not treatment for tardive dyskinesia and may worsen it. The injection label contraindicates use below age 3 and calls for caution in older children. Antimuscarinic effects can worsen confusion, urinary retention, ileus and heat illness, especially with other antimuscarinic drugs. Do not give it reflexively for every symptom after an antipsychotic.
Separate depolarization from repolarization
QRS widening suggesting sodium-channel toxicity follows the bicarbonate pathway described in the cardiotoxic lesson. Isolated QT prolongation is not the same finding and does not automatically call for bicarbonate. Review electrolytes, coexposures and rhythm risk. Current quetiapine labeling calls for cardiovascular monitoring after overdose; do not extrapolate older reassurance about QTc to all patients or antipsychotics.
Support anticholinergic delirium
Antimuscarinic poisoning produces hot dry skin, mydriasis, delirium, tachycardia, urinary retention, ileus, and hyperthermia. Use cooling, fluids, benzodiazepines when indicated, bladder care, and ECG evaluation. Physostigmine can be useful in carefully selected pure anticholinergic toxicity but requires expert exclusion of conduction and seizure hazards.
Screen before reversing antimuscarinic delirium
Physostigmine can reverse central antimuscarinic delirium in carefully selected patients; obtain an ECG and reconstruct the ingestion before use. Atlantic Canada Poison Centre excludes TCA overdose, QRS greater than 100 ms, QTc greater than 500 ms and other conduction abnormalities, and generally avoids mixed or unknown poisoning. A patient with diphenhydramine exposure may have sodium-channel blockade or seizures as well as antimuscarinic effects. Treat that cardiotoxicity or seizure emergency rather than assuming all agitation is an indication for physostigmine.
Use a named slow-dose protocol
Under the Atlantic Canada adult protocol, give physostigmine 0.5 mg IV over 10 minutes and reassess; doses may be repeated every 10 minutes as needed, with no more than 2 mg during the first hour. The endpoint is sustained improvement in delirium and agitation. Maintain continuous cardiac monitoring, reassess neurologic status and have atropine immediately available for excessive cholinergic effects. Rapid administration can cause bradycardia, secretions, respiratory difficulty or seizures. This is one poison-center regimen, not a universal dose for all patients.
Verify concentration and anticipate relapse
Anticholium contains physostigmine salicylate 0.4 mg/mL. For a prescribed 0.5-mg dose, withdraw 1.25 mL before protocol-directed dilution and slow infusion; verify the actual product because formulations may differ. Physostigmine can wear off while the offending drug remains active, so recurrent delirium requires reassessment and possibly further specialist-directed treatment. An initial clear conversation does not establish readiness for discharge. Continue temperature, bladder, hydration and injury assessment as clinically indicated.
Keep alternative antidote evidence qualified
Utah Poison Control describes oral or transdermal rivastigmine as a possible off-label alternative when physostigmine is unavailable, based on limited observational evidence. Its slower onset and longer action are not interchangeable with IV physostigmine. A delirious patient who cannot swallow safely should not receive oral capsules. Antidote availability and route require a current pharmacy and poison-center plan; neither an oral medicine nor a patch replaces urgent resuscitation or sodium-channel-blockade treatment.
Control sympathomimetic heat and struggle
Cocaine, amphetamines, and related stimulants can cause diaphoresis, severe agitation, hypertension, tachycardia, ischemia, seizures, rhabdomyolysis, and hyperthermia. Benzodiazepines, rapid active cooling, fluids, and targeted cardiovascular treatment reduce adrenergic drive. Prolonged physical struggle can worsen acidosis and heat injury.
Cool while controlling agitation
For life-threatening stimulant hyperthermia, AHA 2025 recommends rapid external cooling with ice-water immersion alongside sedation and resuscitation. Cocaine-associated core temperature above 40 °C is a critical warning. Prolonged restraint without effective sedation is hazardous. Benzodiazepines also treat seizures; dantrolene benefit in MDMA hyperthermia remains uncertain.
Separate coronary spasm from conduction toxicity
For acute cocaine-induced coronary vasospasm or hypertensive emergency, AHA favors vasodilators such as nitrates, phentolamine or calcium-channel blockers and does not recommend beta blockers. This acute-poisoning recommendation does not establish a permanent contraindication for every patient with past cocaine use. Sodium bicarbonate or lidocaine is reasonable for cocaine-related wide-complex tachycardia or arrest; refractory cardiogenic shock may warrant extracorporeal support.
Name the bicarbonate indication
Avoid routine urine-pH manipulation for amphetamine toxicity. This does not prohibit bicarbonate for a separate emergency, such as cocaine-associated sodium-channel blockade with QRS widening or selected severe acidosis with cardiovascular complications. Specify the treatment target and monitor ECG, electrolytes and acid-base status.
Use neuromuscular findings for serotonin
Serotonin toxicity after a compatible exposure features clonus, hyperreflexia, tremor, agitation, autonomic instability, and hyperthermia. Stop serotonergic drugs, give benzodiazepines and supportive care, cool aggressively, and escalate severe disease. A drug list plus fever without a compatible clinical assessment is insufficient. Severe rigidity can mask clonus; use the dedicated serotonin-toxicity lesson for diagnostic limits and escalation.
Quick check
Checking for saved practice…
Lesson
Recognize Caffeine and Theophylline Toxicity
Exposure pattern and clinical deterioration determine the response; a concentration threshold is only one part of the decision.
- Caffeine
- Theophylline
- Serial concentrations
- Seizures
- Enhanced elimination
Caffeine and theophylline need exposure-specific interpretation.
Connect concentrations with symptoms and their direction of change.
Coordinate resuscitation and removal with specialists.
Reconstruct the methylxanthine exposure
Identify caffeine versus theophylline, formulation, amount and timing. Ask about supplements, concentrated powders, medicines and repeated dosing. Modified-release theophylline can delay absorption; chronic accumulation changes how a concentration is interpreted.
Recognize the dangerous pattern
Vomiting, tremor and tachycardia may progress to hypotension, dysrhythmias or seizures. Methylxanthines oppose adenosine and increase adrenergic activity. Follow ECG, perfusion, mental status, glucose, potassium and serial theophylline concentrations. A single result cannot establish the final trajectory.
Treat the physiology with toxicology support
Support airway and circulation; use benzodiazepines for seizures, escalating treatment when refractory. Utah Poison Control describes selected beta-blocker use for severe methylxanthine tachycardia, sometimes improving pressure by improving filling. This is a monitored specialist decision, not a universal stimulant rule. Adenosine may fail because of receptor antagonism.
Use a caffeine-specific charcoal protocol
Austin's 2024 protocol offers 50 g activated charcoal within 2 hours and considers 25 g every 2 hours after ingestions above 50 mg/kg; treatment beyond 24 hours is seldom needed. These are attributed protocol choices, not theophylline-derived thresholds. Confirm patient-appropriate dosing, airway protection, bowel function and vomiting risk with toxicology; charcoal must not delay resuscitation or indicated dialysis.
Reassess potassium as caffeine toxicity resolves
Hypokalemia can reflect an intracellular shift rather than a matching total-body deficit. Replace cautiously with serial potassium and ECG assessment because rebound hyperkalemia can occur. Austin's protocol targets 3.0-3.5 mmol/L during this setting; this is not a general potassium target for other illnesses. Vomiting and other concurrent losses still need individual assessment.
Escalate severe caffeine poisoning on its own evidence
Arrange toxicology and nephrology assessment for circulatory collapse, ventricular arrhythmia, seizures or marked neurologic deterioration without waiting for a caffeine assay. The Japanese Society of Clinical and Analytical Toxicology criteria reproduced by Kohara and colleagues also identify a caffeine concentration of at least 140 mg/L as a reason to consider extracorporeal removal; this is a separately attributed caffeine recommendation, not an EXTRIP theophylline cutoff. Hemodialysis is the preferred modality in those criteria, with circulatory support or continuous treatment considered when instability limits its use. The 76-patient retrospective study did not establish an outcome benefit: treatment groups differed in severity, and only two patients had admission caffeine measurements. A concentration can inform care, but absence of a rapid assay must not delay resuscitation or specialist escalation.
Select charcoal by formulation and purpose
For theophylline ingestion at a 20-mg/kg threshold, the 2026 consensus recommends single-dose charcoal through 2 hours for immediate-release and 3 hours for modified-release products; it suggests windows extending to 3 and 6 hours, respectively. Later use requires individualized assessment. It recommends multiple-dose treatment at a 50-mg/kg threshold for either formulation. These are ingested doses, not serum concentrations, and airway and bowel safeguards still apply.
Keep decontamination separate from enhanced elimination
The same consensus suggests an additional charcoal dose at thresholds of 40 mg/kg for immediate-release or 50 mg/kg for modified-release theophylline. This addresses ongoing absorption. Multiple-dose therapy targets absorbed drug and must not delay indicated dialysis. Do not transfer these theophylline thresholds to caffeine.
Plan removal before deterioration
EXTRIP recommends extracorporeal treatment for theophylline-associated seizures, life-threatening dysrhythmias, shock, deterioration or rising concentrations despite optimal care. Acute theophylline above 100 mg/L is another indication. Do not wait for that concentration when a clinical indication already exists. Intermittent hemodialysis is preferred.
Apply chronic thresholds to chronic exposure
EXTRIP suggests removal above 60 mg/L in chronic theophylline poisoning, or above 50 mg/L when the patient is younger than 6 months or older than 60 years. Inability to administer gastrointestinal decontamination is another suggested indication. These recommendations carry low or very low evidence certainty; integrate them with clinical assessment.
Continue monitoring through recovery
Vomiting can prevent safe charcoal administration. Multiple-dose charcoal may enhance elimination when appropriate; EXTRIP advises continuing it during extracorporeal treatment. Its stopping recommendation is clinical improvement or theophylline below 15 mg/L, followed by close monitoring. Rebound and continued absorption matter. These numerical recommendations concern theophylline; severe caffeine poisoning needs its own toxicology-directed removal decision.
Quick check
Checking for saved practice…
Lesson
Recognize Serotonin Toxicity and Treat the Threatened Physiology
Combine exposure and examination, recognize severe rigidity, and distinguish supportive treatment from uncertain adjunctive therapy.
- Hunter criteria
- Clonus
- Rigidity
- Cooling
- Cyproheptadine
Clonus and hyperreflexia help identify the pattern; severe rigidity can obscure them.
Escalate respiratory failure and hyperthermia before waiting for an adjunctive drug response.
Response to cyproheptadine alone does not establish the diagnosis or readiness for discharge.
Establish a plausible exposure
Reconstruct recent initiation, dose increase, overdose, interacting drugs and inadequate washout. Serotonin toxicity is a clinical diagnosis; no laboratory serotonin test confirms it. Examine mental status, autonomic findings and neuromuscular activity together, while assessing infection, withdrawal and other drug syndromes.
Use Hunter findings in context
With a serotonergic exposure, Hunter decision patterns include spontaneous clonus; inducible or ocular clonus with agitation or sweating; tremor with hyperreflexia; or hypertonia with temperature above 38 °C and ocular or inducible clonus. The original rules were developed in overdose patients, so do not treat incidental fever in a stable antidepressant user as diagnostic.
Recognize a dangerous examination change
Severe rigidity can obscure clonus and hyperreflexia. Increasing truncal rigidity, worsening ventilation or rapidly rising temperature requires urgent critical-care escalation even when the usual reflex findings cannot be elicited. A diagnostic rule must not delay treatment of respiratory failure.
Treat physiology before an adjunct
Stop causative drugs, support airway and circulation, use titrated benzodiazepines for agitation or seizures, and actively cool hyperthermia. Severe rigidity may require intubation, ventilation and neuromuscular blockade with appropriate sedation. Monitor ECG, temperature, muscle tone, electrolytes, kidney function and creatine kinase according to severity.
Keep cyproheptadine in its evidence boundary
Cyproheptadine is an off-label serotonin antagonist considered with toxicology input when symptoms persist despite supportive care. Benefit is uncertain; uncontrolled improvement cannot establish that it caused recovery or confirm the diagnosis. It is given enterally, including by tube when appropriate, and does not replace airway protection. Sedation and antimuscarinic effects can complicate reassessment.
Keep the adult adjunct regimen attributed
Utah Poison Control's protocol, updated December 2023 and linked from its current protocol page, lists adult cyproheptadine 8 mg orally, repeatable three times daily with poison-center guidance. Its 2024 educational review describes other loading and repeat schedules. Choose one complete specialist-directed regimen; do not combine schedules or extrapolate the pediatric dose. Improvement after a dose does not establish diagnostic certainty or readiness for discharge.
Name the protocol before the dose
Regimens differ. The Royal Children’s Hospital pediatric guideline lists oral cyproheptadine 2 mg below age 7 and 4 mg from age 7; persistent symptoms may receive the same dose three times daily under that pathway. This is an attributed pediatric protocol, not an adult regimen or a reason to delay intensive care.
Observe the patient and the exposure
The same pediatric guideline calls for admission when symptomatic and at least 12 hours of observation after an at-risk deliberate or significant accidental ingestion. Disposition also requires clinical recovery, appropriate ECG assessment and a self-harm risk plan when relevant. Do not use elapsed time alone as permission to discharge.
Quick check
Checking for saved practice…
Lesson
Match Rescue Therapy to the Broken Biochemical Pathway
Some poisonings are best understood as pathway failures. Dextrose, octreotide, pyridoxine, leucovorin, glucarpidase, and uridine triacetate work only when matched to the right mechanism and timing.
- Hypoglycemia
- Octreotide
- Pyridoxine
- Glucarpidase
- Uridine triacetate
Give dextrose and use octreotide to suppress recurrent sulfonylurea-driven insulin release.
Replace pyridoxine while controlling seizures and acidosis.
Coordinate leucovorin, glucarpidase, or uridine triacetate by mechanism and time window.
Prevent recurrent hypoglycemia
Insulin and secretagogues can produce prolonged or recurrent neuroglycopenia. Give dextrose, nutrition when safe, and frequent glucose monitoring. Octreotide suppresses pancreatic insulin release; pair it with prompt glucose correction for sulfonylurea-induced hypoglycemia rather than waiting for repeated episodes. One normal glucose after a bolus does not establish recovery.
Support the patient while excess insulin remains active
Insulin overdose can cause hypoglycemia and hypokalemia. Use oral carbohydrate only when swallowing is safe; severe neurologic impairment requires emergency parenteral rescue. Continue glucose support and serial reassessment after apparent recovery, correcting potassium appropriately. A normal reading after rescue does not establish that the insulin effect has ended.
Use glucagon without delaying emergency care
When severe hypoglycemia prevents safe oral intake and IV glucose is unavailable, give the available emergency glucagon product according to its own instructions and summon emergency assistance. Glucagon relies on liver glycogen: starvation, adrenal insufficiency or chronic hypoglycemia can reduce its effect. Such patients require glucose treatment. Once swallowing is safe, carbohydrate helps prevent recurrence.
Keep the antidote mechanism straight
Octreotide limits pancreatic insulin secretion; it does not remove injected insulin. Do not replace necessary glucose support for an insulin overdose with the sulfonylurea pathway. Reconstruct the insulin product, concentration, device, delivered units and timing, and use the clinical glucose trajectory to guide ongoing support.
Anticipate delayed sulfonylurea toxicity
A single tablet can cause serious hypoglycemia in a toddler. The RCH pediatric guideline, updated December 2020, recommends 24-hour observation after possible exposure. A normal initial glucose does not clear the exposure; formulate the observation plan with a poison center, considering product, dose and renal function.
Name the octreotide protocol
Utah Poison Control’s September 2024 protocol uses 50 mcg subcutaneously for adults and patients older than 12 years; repeat dosing may be needed every 6 hours if hypoglycemia recurs. It also lists a pediatric weight-based regimen of 1 to 1.5 mcg/kg every 6 hours. Use a complete poison-center plan rather than mixing this with a different institution’s IV infusion schedule. These are microgram doses, not milligrams.
Observe after the antidote wears off
Utah advises monitoring for 12 to 24 hours after the last octreotide dose. Eating and a normal glucose immediately after treatment do not prove sustained recovery. Recheck promptly for symptoms, continue serial glucose checks, and extend care for recurrence. RCH likewise requires normal glucose on a normal diet for 12 hours after its infusion stops before pediatric discharge; these are attributed pathways, not interchangeable discharge timers.
Replace pyridoxine in isoniazid poisoning
Isoniazid depletes functional pyridoxal phosphate and impairs gamma-aminobutyric acid synthesis, causing severe seizures and acidosis. Give intravenous pyridoxine promptly with benzodiazepines and critical support. Use the known dose or an accepted empiric protocol when the ingestion is unknown.
Coordinate methotrexate rescue
Leucovorin bypasses folate antagonism. Glucarpidase enzymatically lowers plasma methotrexate when delayed elimination from impaired kidney function creates toxic concentrations after high-dose therapy. Continue hydration, urine alkalinization, laboratory monitoring, and correctly timed leucovorin because glucarpidase can cleave folates when given too close together.
Match the level to the infusion regimen
The 2018 consensus separates 1 to 8 g/m² infusions over 24 to 42 hours from 8 to 12 g/m² infusions over 6 hours or less. Its 24-hour concentration above 50 micromol/L belongs to the short-infusion pathway with acute kidney injury; do not apply it universally. For a 24-hour infusion, an end-infusion level above 120 micromol/L or a creatinine rise of at least 50% prompts additional monitoring at hour 36. Interpret subsequent levels with the regimen-specific algorithm and renal trajectory. All these times start when methotrexate begins, not when it ends.
Define the glucarpidase indication
The US label requires toxic plasma methotrexate above 1 micromol/L with delayed clearance from renal impairment; compare the result with the dose-specific elimination curve. A concentration above 1 alone is insufficient. Expected clearance is not an indication.
Prepare the enzyme dose
Give 50 Units/kg IV once over 5 minutes, flushing the line before and after. Each 1,000-Unit vial takes 1 mL of normal saline; roll gently, do not shake. Use promptly or refrigerate up to 4 hours; discard unused product. At 60 kg, 3,000 Units requires three vials and 3 mL.
Specify which folinic-acid product is ordered
Levoleucovorin provides the active isomer; its rescue dose is generally half the corresponding racemic leucovorin dose. Confirm the selected protocol and product before substitution. Neither product should be administered intrathecally. Levoleucovorin injection is IV only; calcium-containing products have administration-rate limits.
Tie routine rescue to its chemotherapy regimen
The reviewed leucovorin label uses 15 mg every 6 hours beginning 24 hours after methotrexate starts for its 4-hour high-dose regimen. The corresponding levoleucovorin label uses 7.5 mg. These examples are not universal schedules for every infusion. Vomiting or gastrointestinal toxicity calls for parenteral leucovorin, and delayed clearance can require higher doses and longer treatment.
Escalate using the correct rescue table
In the levoleucovorin label's high-dose rescue table, delayed early elimination or acute renal injury calls for 75 mg IV every 3 hours until methotrexate is below 1 micromol/L, then 7.5 mg every 3 hours until below 0.05 micromol/L. Its separate overdose/impaired-elimination pathway uses different escalation criteria and a body-surface-area dose. Do not splice the tables together or stop because ten doses have been given. After glucarpidase, follow its additional rescue and assay instructions.
Protect leucovorin rescue
Separate leucovorin by at least 2 hours on either side of glucarpidase. Maintain the prior leucovorin dosage for the first 48 hours. Afterward, adjust to methotrexate measurements; continue until concentrations stay below the rescue threshold for at least 3 days.
Check the assay before interpreting rescue failure
DAMPA can falsely elevate methotrexate immunoassay results for approximately 48 hours after glucarpidase. Use chromatography during that period. The 2024 European consensus notes that interference can persist longer, so do not assume an immunoassay becomes reliable automatically at hour 48. Continue indicated hydration and alkalinization; a laboratory result does not replace clinical reassessment. Watch for serious hypersensitivity during administration.
Start the rescue clock at infusion initiation
The 2024 European consensus urges early decisions, aiming for glucarpidase within 48 to 60 hours from the start of high-dose methotrexate. This clock does not start when the infusion ends or kidney injury is discovered. Use the administered dose, infusion duration, serial concentrations and renal trajectory with oncology; do not wait for severe mucositis before mobilizing rescue.
Distinguish toxin removal from kidney support
For severe methotrexate poisoning receiving standard care including folinic acid, EXTRIP suggests against extracorporeal toxin removal without glucarpidase and recommends against adding it to, or substituting it for, glucarpidase. Evidence is very low quality. These recommendations do not cancel usual kidney-replacement indications. Rare early massive exposures warrant expert discussion; dialysis can also remove leucovorin.
Do not clear a daily-dosing error with a low level
Repeated daily use of a prescribed weekly methotrexate dose can cause severe mucosal and marrow toxicity. In low-dose toxicity, a low or undetectable serum concentration does not exclude harm. Stop exposure and urgently assess blood counts, renal function, mucosal injury and infection, with specialist-directed folinic-acid rescue. Routine folic-acid supplementation does not replace that rescue.
Recognize the fluoropyrimidine clock
Uridine triacetate is emergency treatment after fluorouracil or capecitabine overdose, even without symptoms, or selected early-onset severe toxicity. Current labeling emphasizes initiation within 96 hours and a complete 20-dose course. It is not routine treatment for ordinary delayed adverse effects because it can reduce anticancer efficacy.
Prescribe the rescue product and schedule
Vistogard adults receive 10 g orally every 6 hours for 20 doses; pediatric dosing is 6.2 g/m² per dose, capped at 10 g, on the same schedule. Start as soon as possible within 96 hours after fluorouracil or capecitabine ends; benefit beyond that window is unestablished. Mix with soft food and swallow without chewing within 30 minutes. If vomiting occurs within 2 hours, repeat the full dose promptly and keep the next scheduled dose. Xuriden contains the same active ingredient but is labeled for hereditary orotic aciduria with a different daily regimen. Do not substitute its chronic-disease schedule for emergency rescue.
Measure pediatric rescue deliberately
Use a scale accurate to 0.1 g or the label’s graduated quarter-teaspoon method. At BSA 0.50 m², the calculated dose is 3.1 g. The label’s rounded table permits a full 10-g packet at BSA ≥1.44 m². Discard leftovers from opened packets.
Separate oral and tube preparation
Oral doses go into 3 to 4 ounces of soft food, followed by at least 4 ounces of water. For necessary NG or gastrostomy administration, crush granules finely and mix with reconstituted food starch thickener: about 100 mL for 10 g. For pediatric doses below 10 g, use no more than 1 g per 10 mL; flush afterward with water. A 3.1-g tube dose therefore requires at least 31 mL of thickener mixture.
Recover a missed dose without abandoning the course
Give a missed dose as soon as possible, then retain the next regular administration time. Completion means all 20 doses, even if the patient feels well. Document administrations and replacement doses so transfers do not interrupt rescue.
Quick check
Checking for saved practice…
Lesson
Replace the Cofactor While Controlling Seizures
Keep acute pyridoxine rescue separate from chronic supplementation, and connect dose, route and response to an explicit treatment protocol.
- Pyridoxine
- GABA
- Known versus unknown dose
- Unit conversion
- Extracorporeal limits
Establish whether the swallowed amount is credible or unknown.
Use the selected protocol and its initial-dose limits.
Verify concentration, control seizures and support breathing.
Recognize a cofactor emergency
Severe isoniazid poisoning can cause seizures, coma and metabolic acidosis. Impaired pyridoxal-phosphate-dependent GABA synthesis helps explain seizures that resist ordinary treatment. Support airway, ventilation and circulation while obtaining IV pyridoxine and giving benzodiazepines. A routine oral neuropathy-prevention dose is not an acute rescue dose.
Name the dosing source
NJPIES's 2026 antidote protocol uses gram-for-gram pyridoxine for a known adult ingestion, initially capped at 5 g IV. Its pediatric known-dose pathway limits the initial dose to 70 mg/kg, up to 5 g. For an unknown amount it starts adults at 5 g and children at 70 mg/kg, maximum 5 g. These are initial-dose limits, not a universal lifetime ceiling.
Reconcile the label difference
The reviewed isoniazid label instead gives 80 mg/kg for a child with an unknown ingestion. For symptomatic known ingestion it describes gram-for-gram IV pyridoxine over 3-5 minutes. Confirm the selected poison-center protocol rather than silently mixing the label's pediatric dose with another protocol's rate or cap. Treatment should proceed with urgent expert coordination.
Check grams, milligrams and volume
In an adult with a credible ingestion of twelve 300-mg tablets, the total is 3,600 mg, or 3.6 g. Under the stated NJPIES known-dose pathway, 3.6 g pyridoxine is below the initial cap. If the injectable product is verified as 100 mg/mL, the drug volume is 36 mL before any dilution. For a 20-kg child prescribed 70 mg/kg, 1,400 mg equals 1.4 g and 14 mL at that concentration.
Respond to seizures during administration
NJPIES uses 0.5-1 g/minute until seizures cease or the initial dose is delivered; if seizures stop early, the remainder is infused over 4-6 hours. Persistent toxicity can require reassessment and repeat doses at 5-10-minute intervals under toxicology direction. If IV supply is unavailable, arrange expert-directed enteral rescue with airway safeguards while sourcing injectable antidote; do not force oral medication into a seizing patient.
Monitor more than seizure cessation
Follow consciousness, breathing, blood gases, electrolytes and glucose. Severe acidosis requires reassessment after seizure control and respiratory support. Bicarbonate in a hypoventilating patient can worsen carbon dioxide accumulation, so it cannot replace ventilation. The isoniazid label also warns that it interferes with phenytoin metabolism; pyridoxine replacement must not be displaced by repeated conventional anticonvulsants alone.
Reserve extracorporeal removal for its narrow role
EXTRIP suggests against adding extracorporeal treatment to standard care for severe isoniazid poisoning. In the rare situation where standard-dose pyridoxine cannot be administered, it suggests extracorporeal treatment only when seizures resist GABAA-receptor modulators. Both recommendations are weak and based on very low-quality evidence. Dialyzability alone does not establish a clinical indication.
Quick check
Checking for saved practice…
Lesson
Follow Valproate Toxicity Beyond the First Level
Separate drug concentration, metabolic injury and clinical instability when selecting rescue.
- Delayed absorption
- Ammonia
- Levocarnitine
- Concentration units
- Hemodialysis
Support ventilation and perfusion; shock or cerebral edema can independently trigger dialysis.
Investigate encephalopathy even when liver tests are normal.
Follow formulation, serial levels and units; avoid a single-result clearance decision.
Follow the formulation and the patient
Valproate overdose can cause CNS depression, seizures, shock, acidosis and cerebral edema. Enteric-coated products can delay symptoms; obtain the exact formulation and dose history. Follow mental status, breathing, circulation, ECG, glucose, electrolytes, acid-base status, liver tests, ammonia and serial valproate concentrations. Massive exposure can cause delayed marrow suppression, so early improvement does not end follow-up.
Investigate ammonia even with normal liver tests
Unexplained lethargy, vomiting or altered cognition during valproate therapy warrants ammonia testing. Normal liver tests do not exclude hyperammonemic encephalopathy. Topiramate coadministration increases concern even when each drug was tolerated separately. In symptomatic hyperammonemia, stop valproate and arrange treatment and evaluation for underlying urea-cycle disorders; distinguish this from an asymptomatic isolated ammonia elevation that requires monitoring and reassessment.
Recognize topiramate without valproate
Topiramate alone can cause hyperammonemia. New lethargy, vomiting or confusion warrants ammonia testing and urgent evaluation. The prescribing information describes improvement after treatment withdrawal; urgent discontinuation requires clinical monitoring because seizure risk remains. Do not assume the valproate carnitine regimen is established treatment for every topiramate-associated case; involve toxicology in selecting therapy.
Check temperature as well as ammonia
Valproate can cause hypothermia with or without hyperammonemia. The topiramate-valproate combination is another recognized setting, including after starting or increasing topiramate. A core temperature below 35°C with altered mental status requires urgent assessment, supportive care and clinician review of stopping either implicated drug. A normal ammonia result does not clear this combination as the cause.
Use carnitine as an adjunct with stated uncertainty
Levocarnitine is used off-label for valproate-associated hyperammonemia and hepatotoxicity. It supports mitochondrial metabolism but does not replace airway support or indicated dialysis. Evidence for improved clinical outcomes remains limited. Poison-center regimens differ; select one complete plan and follow ammonia, mental status, liver injury and acid-base recovery.
Calculate a named carnitine regimen
The Queensland Poisons Information Centre pathway uses 100 mg/kg IV initially, capped at 6 g, followed by 50 mg/kg every 8 hours, capped at 3 g per dose. A 70-kg patient calculates to 7 g initially and 3.5 g subsequently: the caps give 6 g and 3 g. Confirm formulation and administration instructions with pharmacy; chronic oral supplementation is not an interchangeable acute IV regimen.
Separate dialysis recommendations from suggestions
EXTRIP recommends extracorporeal treatment for valproate above 1,300 mg/L, shock or cerebral edema. It suggests treatment above 900 mg/L, for coma or respiratory depression requiring ventilation, acute hyperammonemia, or pH below 7.10. These are alternative triggers, not a checklist requiring all findings. The evidence quality is very low; the strength of recommendation still differs.
Keep concentration units and stopping criteria explicit
A result in mcg/mL is numerically equal to mg/L: 950 mcg/mL equals 950 mg/L. EXTRIP prefers intermittent hemodialysis; hemoperfusion or continuous renal replacement are alternatives if unavailable. Stopping is supported by clinical improvement or a valproate concentration of 50 to 100 mg/L, with ongoing reassessment. Do not confuse an ingested dose in mg/kg with a serum concentration.
Choose charcoal by formulation and timing
The 2026 charcoal consensus recommends a single dose within 1 hour for valproate ingestions at least 200 mg/kg; it suggests treatment through 3 hours for immediate-release and 4 hours for modified-release exposures at that threshold. Other circumstances require individual assessment; immediate-release use beyond 6 hours is discouraged. It suggests an additional dose above 400 mg/kg, while multiple-dose elimination therapy requires individual assessment. Airway and bowel safeguards remain essential.
Do not use the observation clock as a clearance test
The RCH pediatric pathway describes at least 6 hours for immediate-release and 12 hours for enteric-coated exposures with mild symptoms. Persistent symptoms, severe exposure or abnormal tests require admission and specialist-directed follow-up. Discharge requires clinical recovery, appropriate monitoring and assessment of intentional self-harm. These institutional minimums do not guarantee safety after every overdose.
Quick check
Checking for saved practice…
Lesson
Remove the Lead Source and Verify the Chelator
Lead management connects environmental investigation, a confirmed blood measurement, clinical severity, and a drug-specific treatment plan. A falling laboratory value cannot make an unsafe home safe.
- Venous blood lead
- Exposure control
- Succimer / DMSA
- EDTA salt selection
- Follow-up
Connect the blood result to symptoms, the source, and a safe discharge setting.
Calcium disodium EDTA and disodium EDTA are not substitutes.
A completed prescription is not proof that the exposure problem is resolved.
Confirm and interrupt exposure
CDC uses confirmed venous blood lead levels for management. A capillary result at least 45 mcg/dL needs confirmation within 48 hours, with greater urgency as the level rises. Environmental investigation, iron-deficiency assessment, nutrition, developmental follow-up, and repeat testing remain essential below chelation thresholds.
Escalate according to severity
At confirmed levels at least 45 mcg/dL, obtain neurological assessment, abdominal imaging, and toxicology guidance for decontamination and chelation. Symptoms warrant hospitalization; ongoing exposure or unavailable safe housing can also justify admission. An urgent clinical presentation is not a reason to wait at home for the confirmation deadline.
Identify one medicine correctly
Succimer is DMSA (meso-2,3-dimercaptosuccinic acid), not an additional chelator. Chemet is labeled for children at least 1 year old with blood lead above 45 mcg/dL; it is not labeled for lead encephalopathy. The CDC consultation threshold includes 45 mcg/dL. Distinguish that guidance from the product indication.
Prescribe a changing interval
The labeled oral dose is 10 mg/kg or 350 mg/m² every 8 hours for 5 days, then every 12 hours for 14 days. Check the capsule dosing table. Before treatment, assess CBC, liver and renal function; ANC must exceed 1500/mcL. Monitor CBC and aminotransferases weekly; interrupt for ANC below 1200/mcL. Use the full label for other interruption criteria.
Reject an ambiguous EDTA order
Edetate calcium disodium (CaNa2EDTA) and edetate disodium (Na2EDTA) are different products. Substitution with the disodium salt has caused profound hypocalcemia and fatal cardiac arrest. An order reading only EDTA is incomplete: verify the exact salt with the prescriber and pharmacy before preparation. Do not infer equivalence from similar names or the shared ability to bind metals.
Treat lead encephalopathy as an inpatient emergency
Chemet labeling excludes lead encephalopathy. The March 2026 BAL in Oil label specifies dimercaprol 4 mg/kg deep IM first, followed by 4 mg/kg every 4 hours with calcium disodium EDTA at a separate site; less severe cases may use 3 mg/kg after the first dose. Treatment lasts 2 to 7 days according to response. Obtain a complete toxicology-directed combination order; this is not a chronic lead regimen.
Check BAL contraindications before preparation
The current BAL label contraindicates peanut allergy, hepatic insufficiency except postarsenical jaundice, and concurrent iron products. Screen for G6PD deficiency in high-risk patients and monitor for hemolysis. Monitor renal function, fluid balance and urine alkalinization under the specialist plan. Wait at least 24 hours after the last BAL dose before restarting iron.
Protect renal function during calcium disodium EDTA
The label warns that IV administration in lead encephalopathy with cerebral edema can dangerously raise intracranial pressure and prefers IM treatment. It contraindicates anuria, active renal disease and hepatitis. Establish urine flow, avoid fluid excess in encephalopathy, and stop for anuria or severe oliguria. Confirm route, fluid plan and renal monitoring with the treating toxicologist; a familiar EDTA dose is not enough.
Reconcile the severe-poisoning protocol
NJPIES 2026 uses a different severe-lead regimen: dimercaprol 75 mg/m² IM every 4 hours for 5 days, starting 4 hours before calcium disodium EDTA. For encephalopathy, its EDTA schedule is 1500 mg/m²/day IV, continuously or in 2 to 4 divided doses, for 5 days. This differs from the labels in dose basis and EDTA route. Confirm one complete specialist plan, including antidote availability; do not mix these schedules.
Distinguish WHO guidance from US labeling
For nonpregnant patients with severe lead poisoning, WHO 2021 accepts calcium disodium EDTA alone or with dimercaprol or succimer. Comparative evidence is very uncertain; the traditional BAL-first combination has not been established as superior. WHO permits oral treatment only when airway protection and gastrointestinal absorption are adequate. This differs from US Chemet labeling, which excludes encephalopathy and does not recommend concurrent chelation. A specialist may select an off-label regimen, but the source, route and safeguards must be explicit; these options do not justify giving oral medicine through an unprotected airway. Pregnancy requires a separate maternal-fetal risk assessment, particularly in the first trimester; do not apply this paragraph as a universal pregnancy regimen.
Deliver and monitor oral succimer
A child unable to swallow the capsule may receive its beads on a little soft food, or from a spoon followed by a fruit drink. Stop for infection symptoms; interrupt for rash or mucocutaneous eruptions. Confirmed aminotransferases above five times normal require dose reduction or a temporary stop. Restart after neutropenia only under the label's recovery and risk-benefit criteria.
Plan beyond the last capsule
Recheck blood lead after the course and weekly until stable: redistribution from bone can produce rebound. The Chemet label generally separates repeat courses by two weeks and specifies four weeks after calcium disodium EDTA with or without dimercaprol. The US label does not recommend concurrent chelation with Chemet. Do not interpret the final scheduled dose as proof that the exposure and follow-up problem is resolved.
Quick check
Checking for saved practice…
Lesson
Count Elemental Iron and Follow the Clinical Course
An iron-containing supplement can cause a serious overdose. Reconstruct the elemental amount, interpret the timed serum concentration alongside the patient's condition, and treat systemic toxicity with poison-center support.
- Elemental iron
- Delayed deterioration
- Serum iron
- Deferoxamine
- Infusion safety
Tablet count × elemental amount per tablet ÷ body weight.
Prescribed mg/kg/hour × body weight; track the cumulative dose.
Divide the prescribed mg/hour by the verified final mg/mL.
Calculate the exposure from the product
Use the package's elemental-iron content. Twelve tablets containing 65 mg elemental iron each represent 780 mg; in a 12-kg child, that is 65 mg/kg. Multiplying the salt's 325-mg strength instead would answer a different question. Utah Poison Control associates exposures above 60 mg/kg elemental iron with high risk of severe toxicity.
Do not mistake quiet symptoms for recovery
Early gastrointestinal injury may give way to an apparently quieter interval before shock, acidosis or liver injury. Not every patient follows every stage. Obtain serum iron around 4 to 6 hours after ingestion; delayed-release products can require later reassessment. Ferritin and total iron-binding capacity do not substitute for the acute serum measurement.
Choose decontamination that can work
Activated charcoal does not bind iron. Abdominal imaging can identify retained tablets and inform specialist-directed whole-bowel irrigation. Resuscitation, serial observations and metabolic testing remain central; a decontamination procedure cannot replace management of shock.
Recognize the indication for chelation
Utah's 2025 protocol recommends deferoxamine for severe toxicity, iron above 500 mcg/dL even with mild symptoms, or above 350 mcg/dL with severe symptoms or tablets on abdominal imaging. Integrate concentration, timing and physiology with toxicology consultation. A delayed laboratory result should not postpone treatment of a convincing severe presentation.
Name the protocol before programming
Utah's protocol starts IV deferoxamine at 5 mg/kg/hour and titrates toward 15 mg/kg/hour if blood pressure permits. Reassess after the first 1,000 mg; subsequent rate and total exposure depend on response. The protocol generally limits treatment to 6 to 8 g in 24 hours and acknowledges uncertain optimal dosing. This is specialist guidance, not the FDA-labeled regimen.
Keep the labeling distinction visible
Desferal labeling instead specifies IM treatment when not in shock and slow IV treatment for cardiovascular collapse, with a 6-g/24-hour maximum. Its acute IV schedule starts with 1 g at no more than 15 mg/kg/hour, followed if needed by 500-mg doses over 4 to 12 hours at no more than 125 mg/hour. Do not combine pieces of these schedules into an undocumented hybrid order.
Monitor both illness and treatment
Utah recommends baseline CBC, chemistry, blood gas, lactate and INR with reassessment at least every 4 hours. Hypotension and respiratory injury can reflect poisoning or treatment. Urine discoloration is an observation, not a stand-alone efficacy endpoint. Desferal is contraindicated in severe renal disease or anuria. Escalate renal impairment to specialists; verify reconstitution and further IV dilution, avoiding rapid injection.
Separate chronic overload from acute rescue
Transfusional iron overload uses a distinct long-term regimen; chronic subcutaneous pump dosing is not an acute-overdose order. Prolonged deferoxamine also requires ocular/auditory monitoring and attention to Yersinia and mucormycosis. Primary hemochromatosis has a different management pathway, generally phlebotomy. The shared word iron does not establish interchangeable tests, routes or schedules.
Check the rate and the cumulative dose
For an explicitly prescribed 15 mg/kg/hour infusion in a 20-kg patient, the rate is 300 mg/hour. If pharmacy verifies a final concentration of 3 mg/mL, the pump rate is 100 mL/hour. A correct hourly calculation does not authorize continuing indefinitely: reconcile the chosen protocol, fluid load, delivered total and reassessment time. At this unchanged rate, 24 hours would deliver 7,200 mg.
Quick check
Checking for saved practice…
Lesson
Separate Aluminum Treatment From Acute Iron Rescue
The same chelator can appear in different treatment pathways. Aluminum toxicity in kidney disease requires an exposure investigation and a nephrology-led plan.
- Exposure prevention
- Bone and neurological injury
- Diagnostic context
- Label discrepancy
- Dialysis coordination
Distinguish aluminum accumulation from acute iron ingestion.
Confirm the dose interval and relationship to dialysis.
Document specialist rationale, label restrictions and monitoring.
Look for continued exposure
KDIGO recommends avoiding long-term aluminum-containing phosphate binders in CKD G3a to G5D and preventing aluminum contamination of dialysate. Review medication ingredients and dialysis-system exposure when toxicity is suspected; changing the chelator does not remove the source.
Interpret the clinical pattern
Aluminum accumulation can cause bone pain, proximal weakness, fractures and encephalopathy. Serum aluminum alone may poorly represent chronic tissue burden. Nephrology may use specialized serum testing or bone biopsy in context. A dialysis-specific deferoxamine serum mobilization test is distinct from comparing a provoked urine sample with untreated reference ranges.
Name the source and its limits
A 2021 Brazilian nephrology guideline describes IV deferoxamine 5 mg/kg once weekly over 30 to 60 minutes, coordinated with dialysis. The aluminum-chelator complex can be removed by dialysis. This is specialist guidance, not a U.S. labeled aluminum regimen. Do not transfer the acute iron infusion rate into this pathway.
Resolve the label conflict explicitly
U.S. Desferal labeling contraindicates use in severe renal disease or anuria. A specialist aluminum protocol in dialysis therefore requires explicit reconciliation of this contraindication and a documented rationale. A general antidote table cannot resolve that decision. Verify the complete plan with nephrology, toxicology and pharmacy before administration.
Monitor for treatment-related harm
The label warns that mobilizing aluminum may provoke neurological deterioration or seizures, precipitate dialysis dementia, lower calcium and worsen hyperparathyroidism. Prolonged deferoxamine also requires visual and hearing assessment and attention to serious infections. New neurological findings after treatment must not automatically be attributed to progression of the original poisoning.
Quick check
Checking for saved practice…
Lesson
Identify the Chemical Form Before Interpreting the Test
A metal name on a laboratory report is the beginning of an exposure assessment. Chemical form, route, timing, symptoms and specimen collection determine what that result can support.
- Arsenic speciation
- Seafood history
- Mercury vapor
- Provoked urine testing
- Chelation boundaries
A shared element name does not make exposures clinically equivalent.
Document meals, symptoms, sampling and any prior chelator.
Match the assay and reference population to the question being asked.
Recognize serious arsenic exposure
Inorganic arsenic can cause severe gastrointestinal illness, volume depletion, shock and multiorgan injury. Chronic exposure may present with skin changes or neuropathy. Investigate water, work, hobbies and imported remedies. Urgent stabilization and toxicology-directed treatment should not wait for delayed laboratory confirmation.
Ask which arsenic was measured
ATSDR favors a 24-hour speciated urine test for recent exposure. Total urine arsenic also includes relatively nontoxic seafood forms consumed within the preceding 48 hours. Spot urine arsenic with creatinine can help in emergencies. Hair and nail results have limited clinical utility without accepted reference ranges.
Separate acute rescue from chronic source control
Early expert-selected chelation, including dimercaprol in appropriate acute arsenic cases, may help. Chronic management prioritizes identifying and ending exposure, supportive care and follow-up; lowering a number does not guarantee reversal of established injury.
Treat mercury vapor as an inhalation hazard
Elemental mercury spilled indoors can generate hazardous vapor. Inhalation can injure lungs, kidneys and the nervous system; swallowing a small amount of elemental liquid has different absorption and risk. This distinction cannot be transferred to mercury salts or organic mercury compounds. Establish the actual material and route with poison specialists.
Keep cleanup from becoming another exposure
Do not use an ordinary vacuum cleaner on spilled elemental mercury: it can increase airborne mercury and spread contamination. Arrange poison-center and environmental/public-health assistance. Treat breathing or circulatory failure promptly, remove ongoing exposure safely and assess others sharing the contaminated setting.
Describe chelation evidence honestly
Mercury chelation requires specialist assessment rather than a universal antidote rule. CDC documented off-label succimer treatment after severe elemental-vapor exposure in two siblings. That report establishes a clinical use outside the labeled indication; it does not prove a regimen suitable for every mercury compound or guarantee neurological recovery.
Keep the BAL mercury indication narrow
The March 2026 US BAL label specifies acute mercury poisoning within 2 hours after ingestion and excludes chronic mercury poisoning. Its mercury schedule is 5 mg/kg deep IM initially, then 2.5 mg/kg once or twice daily for 10 days. This is a labeled regimen to reconcile with toxicology, not a standing order for any elevated mercury measurement, vapor exposure or organic mercury exposure.
Separate organic mercury treatment from metal removal
Stop the exposure and obtain specialist assessment. Austin's 2023 organic-mercury guidance reserves consideration of chelation for large acute exposures or clinical poisoning with evidence of a large body burden; mildly elevated blood mercury associated with seafood rarely requires specific treatment. DMSA and DMPS can increase elimination, but this does not establish reversal of neurological injury. WHO's pesticide-treatment guidance warns against BAL in organic mercury exposure because animal evidence suggests redistribution into the brain. Do not transfer BAL's acute-ingestion label regimen to methylmercury poisoning.
Investigate inorganic mercury beyond the spill
Mercury-containing skin creams can expose both users and household members. Ask about personal-care products and shared surfaces when renal or neurological findings cluster in a home. CDC's household investigation supports ending exposure and assessing kidney function; an elevated urinary concentration alone is not a chelation order. Involve toxicology and public health in patient assessment and safe source removal.
Match the mercury specimen to the suspected form
ATSDR's 2024 profile identifies urine mercury as useful for inorganic mercury and elemental-vapor exposure. For methylmercury, whole-blood methylmercury and appropriately collected hair measurements are more informative; urine total mercury is not a useful marker of methylmercury exposure. Total blood mercury includes different forms, and metabolism further complicates interpretation. Select the assay with the laboratory and exposure history rather than treating every mercury result as equivalent.
Reject a provoked reference-range comparison
ACMT recommends against post-chelator challenge urine testing to diagnose metal poisoning. Chelators increase urinary metal excretion even in people without poisoning. Comparing that sample with a reference range for untreated people can create a false diagnosis and unnecessary treatment. Record prior chelation and obtain appropriately selected, validated testing.
Keep copper chelation tied to its indication
Penicillamine removes excess copper and is labeled for Wilson disease, an inherited copper-accumulation disorder. That chronic indication does not establish an emergency regimen for every copper exposure. Identify the compound, route and clinical injury with toxicology before selecting acute treatment. Wilson disease needs ongoing specialist treatment and monitoring; penicillamine and trientine remove copper, whereas zinc reduces intestinal absorption. Acute liver failure requires urgent transplant-center assessment rather than waiting for an oral chelator response.
Check penicillamine administration and harm
CUPRIMINE is taken on an empty stomach, at least one hour before or two hours after meals, and at least one hour apart from other medicines, milk, antacids, zinc or iron. Its toxicity requires close supervision. Do not equate its copper-binding mechanism with freedom from renal or marrow injury, or substitute another chelator without reviewing the disease-specific plan.
Recognize the labeled gold-poisoning option
The March 2026 BAL in Oil label includes arsenic and gold poisoning. Selection depends on confirmed or strongly suspected exposure and clinical assessment, not the mere presence of a metal in a product. Its deep-IM-only route, peanut-allergy contraindication, renal precautions and prohibition on concurrent iron still apply. The gold indication does not authorize transferring a lead or mercury dosing schedule; obtain the complete indication-specific toxicology order.
Verify the drug as carefully as the toxin
Dimercaprol (BAL) and succimer (DMSA) are distinct drugs. The March 2026 BAL in Oil label specifies deep intramuscular use and contraindicates peanut allergy because the formulation contains peanut oil. It warns against use for iron, cadmium or selenium poisoning because the complexes can increase toxicity. Check the actual product, allergy history, organ function and specialist protocol rather than treating chelators as interchangeable.
Quick check
Checking for saved practice…
Lesson
Match the Countermeasure to the Contaminant
Identify the substance and route before choosing an emergency countermeasure. A radiation alert alone does not select a drug.
- Internal contamination
- Prussian blue
- Thallium dialysis
- Radioiodine
- Public-health direction
An alert alone does not identify the contaminant inside a patient.
Match the product to the target and the patient.
Track response, adverse effects and the need for additional support.
Trap the appropriate contaminant
Prescription insoluble Prussian blue binds cesium and thallium in the gut, interrupting reabsorption. Radiogardase treats internal radioactive cesium or radioactive/nonradioactive thallium contamination.
Verify dose and evidence separately
The label lists 3 g orally three times daily for adults/adolescents and 1 g three times daily for ages 2 to 12. Each capsule contains 0.5 g. Pediatric thallium safety and efficacy are not established; the pediatric cesium evidence must not be generalized.
Plan the course and monitoring
Give with food; capsules may be opened into bland food or liquid. Treatment can exceed 30 days. Follow measured elimination, weekly CBC, chemistry and electrolytes; monitor constipation and hypokalemia. Slowed bowel transit can increase gastrointestinal radiation exposure. Blue stool is expected.
Use contaminant-specific stopping criteria
Do not stop Prussian blue automatically at day 30. For cesium, the label bases duration on weekly urine and fecal radioactivity measurements. For thallium, it specifies a normal 24-hour urine test below 5 micrograms/L; radioactive thallium also requires an acceptable radiation level. This is a concentration in a timed urine collection, not 5 micrograms excreted per day. Radiation-safety and toxicology teams interpret the results and arrange follow-up.
Avoid a blanket rule for metals
Unlike many other metals, thallium can be adsorbed by charcoal. The 2026 consensus supports selected single, additional and multiple-dose use, while acknowledging very low-quality evidence and limited human outcome data. It does not establish charcoal as superior or equivalent to Prussian blue. Coordinate the whole treatment plan with toxicology.
Escalate severe thallium poisoning
EXTRIP recommends extracorporeal treatment for severe thallium poisoning, preferably intermittent hemodialysis, started as soon as possible, ideally within 24 to 48 hours. Strong clinical suspicion can justify action before a concentration returns. These recommendations carry very low-quality evidence grades; involve toxicology and nephrology rather than treating Prussian blue as sufficient for every patient.
Separate dialysis cessation from antidote cessation
EXTRIP suggests continuing extracorporeal treatment until serum thallium remains below 0.1 mg/L for at least 72 hours, accounting for redistribution from tissues. This is a weak recommendation supported by very low-quality evidence, not a proven safe concentration. Persistent neurologic injury may outlast removal; stopping decisions require toxicology and nephrology assessment of serial levels, clinical course and treatment complications. The serum dialysis criterion must not replace the urine criterion used for Prussian blue.
Keep thyroid blockade specific
Potassium iodide (KI) reduces thyroid uptake of radioactive iodine. It does not protect other organs or cover cesium, thallium or external radiation. Use FDA-approved KI only when directed by public-health officials or a clinician; iodine supplements and table salt are not substitutes. Age, pregnancy and predicted exposure affect eligibility. Adults over 40 may still qualify at sufficiently high predicted thyroid exposure.
Select the KI dose by age and product
After officials establish the indication, FDA dosing is 16 mg from birth through 1 month; 32 mg over 1 month through 3 years; 65 mg over 3 through 12 years; and 65 mg for adolescents through 18 years, increased to 130 mg above 150 lb. Adults and pregnant or lactating patients receive 130 mg. For the 65-mg/mL solution, the published volumes are 0.25, 0.5, 1 and 2 mL, respectively. The small pediatric doses are rounded: 0.25 mL contains 16.25 mg and 0.5 mL contains 32.5 mg. Use the product instructions and a marked dosing device.
Coordinate timing with the emergency response
CDC identifies the most effective window as the 24 hours before through 4 hours after radioiodine exposure. This describes effectiveness, not permission to self-start KI before an emergency. One dose protects for about 24 hours; further doses require official direction while exposure continues. Taking larger or more frequent doses does not improve protection.
Protect infants separately from their mothers
Maternal KI does not provide enough through breast milk to protect an infant. Arrange the infant's own indicated dose and thyroid follow-up, particularly for neonates receiving any KI. Prioritize sheltering, evacuation and safe food access to avoid repeat doses in pregnancy, lactation and infancy. If safe alternatives are available, temporarily interrupt breastfeeding during radioiodine exposure; do not leave an infant without food when breast milk is the only option. Any necessary repeat dosing requires public-health and clinical guidance.
Screen for KI-specific risks
Check prior KI or iodine sensitivity, dermatitis herpetiformis, hypocomplementemic vasculitis, and nodular thyroid disease with heart disease. FDA advises avoidance in these settings. Shellfish allergy alone does not establish KI hypersensitivity. Graves disease, multinodular goiter and autoimmune thyroiditis require caution, particularly with repeated treatment.
Avoid false reassurance
KI does not reverse established thyroid injury or replace sheltering and official evacuation instructions. Repeat doses require direction, with particular caution in neonates because hypothyroidism can impair development. A medicine request should therefore trigger identification of the actual emergency, not automatic dispensing of a generic radiation antidote.
Quick check
Checking for saved practice…
Lesson
Match Bleeding Rescue to the Anticoagulant
Distinguish drug-specific binding from factor replacement, calculate the right product dose and reconcile historical reversal tables with current U.S. safety updates.
- Idarucizumab
- Vitamin K
- Four-factor PCC
- Current factor Xa pathway
Bind the specific drug; reassess recurrent anticoagulant effect.
Replace deficient factors and sustain their production.
Use current U.S. options; the warfarin INR table does not apply.
Decide whether reversal is warranted
Control the bleeding source and stabilize circulation while confirming the drug, last dose, kidney function and bleeding site. Antidote or hemostatic therapy is generally reserved for life-threatening bleeding or major bleeding that persists despite initial care, rather than routine treatment of a minor bruise. Urgent procedures require their own exposure and bleeding-risk assessment.
Use the dabigatran-specific product
PRAXBIND is indicated for dabigatran reversal in life-threatening or uncontrolled bleeding or emergency surgery/urgent procedures. Give 5 g IV as two consecutive 2.5-g/50-mL vials: the total volume is 100 mL. Do not mix with other medicines or run another infusion through the same access during administration; flush an existing line with normal saline first. Renal impairment does not require a reduced idarucizumab dose.
Reassess recurrence and restart separately
After idarucizumab, recurrent clinically relevant bleeding with elevated coagulation parameters, or another urgent procedure with elevated parameters, may justify a further 5 g; repeat-treatment evidence is limited. The label permits dabigatran restart after 24 hours, but that is not an instruction to restart despite ongoing bleeding. Restore anticoagulation when medically appropriate.
Replace warfarin-depleted factors and sustain recovery
KCENTRA is labeled for urgent adult vitamin K antagonist reversal with acute major bleeding or urgent surgery. Give vitamin K concurrently because factor replacement is temporary. The labeled Factor IX-unit doses are 25 units/kg for INR 2 to below 4, 35 for INR 4 through 6, and 50 for INR above 6, capped at 2,500, 3,500 and 5,000 units respectively. Dosing weight is capped at 100 kg.
Use vitamin K without waiting for it to replace factors
For major warfarin bleeding requiring reversal, the ACC pathway uses vitamin K 5 to 10 mg IV with rapid factor replacement. IV vitamin K acts over hours; it cannot provide immediate hemostasis alone. Subcutaneous absorption is unpredictable for this emergency, despite the injectable label’s general preference for that route.
Respect the current vitamin K warning
The current phytonadione label warns of severe or fatal hypersensitivity with IV or IM use, including reactions despite dilution. When IV administration is necessary, do not exceed 1 mg/minute and monitor with resuscitation available. The ACC pathway describes diluted administration over 15 to 30 minutes. Slower delivery does not eliminate reaction risk. Verify the formulation, diluent and concentration.
Prepare and deliver KCENTRA deliberately
Use the supplied sterile water: 20 mL for the nominal 500-unit kit or 40 mL for the 1,000-unit kit. Swirl gently without shaking; use actual Factor IX potency. Start promptly or within 4 hours after reconstitution, using a separate infusion line. The labeled rate is 0.12 mL/kg/min, capped at 8.4 mL/min. For 60 kg, that is 7.2 mL/min or 432 mL/hour; at 90 kg, the cap limits delivery to 504 mL/hour.
Follow hemostasis as well as INR
Check clinical bleeding and INR during and after factor replacement. A rapidly improved INR does not itself prove the bleeding source is controlled. Reassess thrombosis risk and anticoagulation resumption separately; do not use a laboratory target as an automatic repeat-PCC order.
Calculate the correct category and screen the product
For an 80-kg patient with INR 5, the labeled KCENTRA dose is 80 times 35 = 2,800 Factor IX units. Verify actual vial potency. Repeat dosing is not recommended by the label. KCENTRA contains heparin and is contraindicated with known HIT, DIC or severe hypersensitivity to its components; balance reversal against thrombotic risk.
Match protamine to recent UFH exposure
Protamine dosing follows remaining heparin, not the total lifetime dose. Approximately 1 mg neutralizes 100 USP heparin units; the requirement falls as IV heparin clears. Give slowly over 10 minutes, with doses not exceeding 50 mg under the product instructions. A prescribed 30-mg dose from 10 mg/mL requires 3 mL before any dilution.
Anticipate protamine reactions and excess dosing
Monitor for hypotension, bradycardia, anaphylaxis and pulmonary complications with resuscitation available. Prior protamine exposure, including NPH insulin, changes risk assessment. Excess protamine can itself impair coagulation; persistent bleeding requires reassessment rather than automatic escalation.
Apply the enoxaparin timing rule
The Lovenox label uses 1 mg protamine per 1 mg enoxaparin given within the preceding 8 hours; after 8 hours, 0.5 mg/mg may be used. A needed second dose uses 0.5 mg/mg. At 12 hours or later, reversal may be unnecessary, but assess ongoing bleeding and renal persistence. These ratios do not authorize rapid administration or bypass protamine dose limits.
Do not equate partial reversal with recovery
Protamine reverses at most about 60% of enoxaparin anti-Xa activity. Although the overdose section mentions prolonged aPTT 2 to 4 hours after treatment when discussing a second dose, the monitoring section says PT/aPTT inadequately measure enoxaparin effect. A normal aPTT therefore cannot establish complete reversal; use clinical assessment and appropriate anti-Xa testing with specialist guidance.
Update the factor Xa pathway
RxPrep 2023 lists andexanet for apixaban/rivaroxaban. FDA subsequently concluded that serious thrombotic risks outweigh benefits, and U.S. commercial sales ended in December 2025. Use current source-control and institutional hemostatic pathways. Four-factor PCC use for factor Xa inhibitor bleeding is off-label; do not transfer the warfarin INR-based table to a DOAC exposure.
Quick check
Checking for saved practice…
Lesson
Make Rare Antidotes Operational Before the Emergency
A lifesaving product is useful only when the team can identify the indication, locate it, prepare it, administer it, monitor it, and replace it. Preparedness also protects medication continuity during disasters.
- Antidote stock
- Preparation
- Envenomation
- Rabies exposure
- Disaster continuity
Match local risk, transfer time, storage, expiry, and replenishment.
Place dosing, mixing, compatibility, monitoring, and consultation at the bedside.
Preserve access to critical medicines during disasters and coordinate envenomation and rabies response.
Build an antidote system
Use risk assessment and regional transfer time to determine stock. Standardize preparation cards, mixing supplies, dosing support, monitoring, storage, and expiry review. Simulate rare high-risk workflows such as hydroxocobalamin, digoxin immune Fab, high-dose insulin, and snake antivenom.
Respond safely to snakebite
For suspected North American pit viper envenomation, remove constricting items, immobilize the limb, transport promptly, and obtain poison-center guidance. Avoid incision, suction, ice, electric shock, and tight tourniquets. Progressive local injury, hematologic toxicity, or systemic effects can require antivenom and serial reassessment.
Match the antivenom to the snake group
CroFab and Anavip are treatments for North American pit viper envenomation; Anavip is not restricted to rattlesnake bites. Coral snakes require a separate product and specialist pathway. A table that places several snakes beside one list of medicines does not establish that every medicine treats every snake.
Keep first aid exposure-specific
A wrapped cold compress can help a spider bite, but ice is inappropriate first aid for a suspected pit viper bite. Do not transfer instructions between animals simply because both exposures break the skin. Obtain poison-center advice without delaying emergency transport.
Use public health for rabies decisions
Wash animal wounds immediately. Species, geography, exposure type, animal testing or observation, and prior vaccination determine postexposure prophylaxis. For an unvaccinated patient with a qualifying exposure, vaccine and human rabies immune globulin are used according to current public-health guidance. For an immunocompetent person with documented prior complete rabies vaccination, CDC uses vaccine on days 0 and 3 without HRIG. Confirm vaccination history and special circumstances with public health.
Preserve medication access during disasters
Plan for cold chain, power loss, controlled substances, documentation, alternate dispensing, surge demand, accessible communication, and vulnerable patients. Prioritize continuity for insulin, antiseizure drugs, transplant medicines, anticoagulants, oxygen-related therapies, and other treatments where interruption can rapidly cause harm.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 266 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- CPSC staff. Poison Prevention Packaging: A Guide for Healthcare Professionals (January 2023).
- DailyMed. CUPRIMINE: copper chelation indication, administration and safety.
- NIDDK. Wilson disease treatment: chelation, zinc and lifelong therapy.
- EXTRIP. Acetaminophen extracorporeal treatment recommendations
- Austin Clinical Toxicology. Caffeine, version 3 (September 2024)
- Austin Clinical Toxicology. Organic mercury (2023)
- WHO. Sound management of pesticides (2006), module 7 B 17: organic mercury
- WHO. Clinical management of exposure to lead (2021), section 7.3.9
- Austin Clinical Toxicology: Atropine (November 2024)
- Queensland Poisons Information Centre: Atropine
- Kohara et al. Caffeine extracorporeal treatment study and attributed Japanese criteria (2026 issue)
- Utah Poison Control. Antidote stocking: institution-specific assessment.
- FDA. Safe Drug Use After a Natural Disaster.
- RCH. Benzodiazepine poisoning (2019): pediatric supportive care and observation.
- ACMT. Interpretation of Urine Opiate and Opioid Tests (2021/2022).
- ATSDR archived educational guidance. Ethylene glycol laboratory assessment: diagnostic limitations.
- NIMH. Adult Emergency Department Brief Suicide Safety Assessment Guide: assessment and disposition after a positive screen.
- EXTRIP. Theophylline: extracorporeal treatment recommendations.
- EXTRIP systematic review (2015): theophylline poisoning and evidence limitations.
- Utah Poison Control (2025). Caffeine and theophylline toxicity.
- DailyMed. Benztropine injection (March2026): acute dystonia, pediatric contraindication and adverse effects.
- DailyMed. Seroquel: overdose support and QT precautions.
- RCH. Quetiapine poisoning (2019): formulation and delayed toxicity; interpret alongside current labeling.
- RCH. Ethanol poisoning: pediatric assessment and supportive care.
- ASAM. Alcohol Withdrawal Management guideline (2020).
- UK alcohol treatment guidelines (2025), section16.9.4: Wernicke prevention and treatment.
- Vitamin K1 injection prescribing information (October 2025)
- ACC 2020 full bleeding pathway: vitamin K and factor replacement
- Protamine sulfate prescribing information (November 2024)
- Lovenox prescribing information: monitoring and overdose
- FDA Andexxa safety update (December 2025)
- PRAXBIND prescribing information
- KCENTRA prescribing information
- ACC bleeding consensus (2020; andexanet recommendation superseded by U.S. safety update)
- Dunkley et al. Hunter Serotonin Toxicity Criteria (2003)
- Royal Children’s Hospital: serotonin toxicity (July 2021)
- Nguyen et al. Cyproheptadine outcomes in California Poison Control cases (2019; publisher study summary).
- Utah Poison Control. Serotonin syndrome protocol (document updated December 19, 2023).
- Utah Poison Control: cyproheptadine evidence and treatment boundaries (August 2024)
- Atlantic Canada Poison Centre: adult physostigmine protocol (March 2023)
- Utah Poison Control: physostigmine and rivastigmine (February 2024)
- DailyMed: Mestinon cholinergic crisis, masking risk and renal elimination
- DailyMed: DuoDote dose, weight restriction and device instructions
- DailyMed: atropine poisoning-specific maintenance dosing
- Australian national chemical-exposure guidelines: organophosphates, pages 141-142
- DailyMed: PROTOPAM pralidoxime preparation, dosing and warnings
- DailyMed: ready-to-use sodium nitroprusside toxicity and renal infusion limits
- DailyMed: NITHIODOTE prescribing information (December 2024)
- NJPIES: pyridoxine antidote-use protocol (February 2026, pages 39-40)
- DailyMed: isoniazid overdose management and label dosing
- EXTRIP: isoniazid extracorporeal treatment recommendations
- FDA: preventing accidental e-liquid exposure
- NIOSH: nicotine systemic toxicity and supportive treatment
- Royal Children's Hospital: nicotine poisoning (institutional pediatric guideline, January 2019)
- NPIC: mothball health effects (April 2026)
- NPIC: naphthalene toxicology technical fact sheet (archived)
- National Capital Poison Center: mothball ingredient and toxicity distinctions
- NIOSH: naphthalene exposure routes and target organs
- National Capital Poison Center: gasoline and diesel fuel toxicity
- Royal Children's Hospital: hydrocarbon poisoning (institutional pediatric guideline, June 2017)
- ATSDR: gasoline medical management (archived; reviewed with current poison-center advice)
- DailyMed. PROVAYBLUE: dosing, renal impairment, contraindications and boxed warning
- Iolascon et al. EHA/EuroBloodNet recommendations for methemoglobinemia (2021)
- FDA. Safely soothing teething pain in infants and children
- DailyMed. OTC Narcan 4 mg Drug Facts (April 2026)
- DailyMed. OPVEE nalmefene nasal spray prescribing information
- ACMT/AACT. Nalmefene should not replace naloxone as the primary opioid antidote
- ACMT. Expired naloxone when unexpired drug is unavailable (March 2026)
- DailyMed. Flumazenil injection: contraindications, warnings and pediatric use (updated June 2026)
- Utah Poison Control. High-dose insulin therapy: administration and monitoring
- AHA 2025. Critical-poisoning antidote doses, Table 4
- ASRA. Local anesthetic systemic toxicity checklist (2020, current pending planned 2027 revision)
- ASAM/AAAP. Stimulant use disorder guideline: acute intoxication and complications
- IPCS. Amphetamine poison information monograph: historical abandonment of forced acid diuresis
- MSD Manual Professional. Amphetamines: enhancing excretion (reviewed June 2026)
- EXTRIP: Barbiturate poisoning recommendations
- Hoegberg et al. Clinical Toxicology Recommendations Collaborative: activated charcoal (2026)
- AACT/EAPCCT. Whole-bowel irrigation position paper update
- National Capital Poison Center. First aid for poisonings
- National Capital Poison Center. Online triage eligibility and telephone help
- Brazilian Journal of Nephrology. Aluminum intoxication in CKD (2021)
- KDIGO. CKD-MBD guideline and resources
- DailyMed. Radiogardase prescribing information
- EXTRIP. Full thallium recommendations and cessation rationale (2012)
- EXTRIP. Thallium recommendations
- FDA. Potassium iodide dosing and precautions
- HHS REMM. Potassium iodide and infant follow-up
- CDC. Potassium iodide in radiation emergencies (2025)
- ATSDR. Arsenic clinician brief (2025)
- CDC NIOSH. Elemental mercury emergency response card
- CDC MMWR. Elemental mercury poisoning in two siblings (2023)
- ATSDR. Mercury toxicological profile (2024), chapter 3: biomarkers
- CDC MMWR. Mercury exposure from skin-lightening creams: household investigation
- ACMT. Against post-chelator challenge urinary metal testing
- NJPIES. Antidote Use Guideline (February 2026): severe lead protocols
- FDA. BAL in Oil prescribing information (March 2026)
- Utah Poison Control. Acute iron poisoning protocol, revised January 2025
- Utah Poison Control. Iron toxicity assessment and management
- DailyMed. Desferal: acute versus chronic regimens and safety
- DailyMed. Edetate calcium disodium: encephalopathy and renal safeguards
- DailyMed. Chemet: succimer indication, dosing, monitoring, and chemical identity
- CDC. Recommended actions based on childhood blood lead level
- CDC MMWR. Fatal hypocalcemia associated with EDTA salt errors
- DailyMed. Xuriden indication and dosage
- CDC MMWR. Mushroom product investigation and muscarine distinction (2024)
- DailyMed. Acetylcysteine oral/inhalation solution: dosing and route restrictions
- Utah Poison Control. Mushroom ingestion: diagnosis and management
- CDC MMWR. Amanita poisonings in northern California, 2025-2026
- ACMT. Duration of intravenous acetylcysteine therapy (2026 update)
- DailyMed. Anavip indication and administration
- CDC NIOSH. Venomous spiders and first aid
- Pfizer. North American Coral Snake Antivenin prescribing information
- American Heart Association. Adult and Pediatric Special Circumstances of Resuscitation: Poisoning.
- Dart RC, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement.
- American Academy of Clinical Toxicology. Position Statements and Recommendations.
- American College of Medical Toxicology. Management Priorities in Salicylate Toxicity.
- National Capital Poison Center. Button Battery Ingestion Triage and Treatment Guideline.
- DailyMed. Acetadote acetylcysteine injection prescribing information.
- DailyMed. Narcan naloxone nasal spray prescribing information.
- DailyMed. Cyanokit hydroxocobalamin prescribing information.
- DailyMed. Fomepizole injection prescribing information.
- DailyMed. Topiramate: withdrawal, hyperammonemia and hypothermia (revised April 2026).
- DailyMed. Fomepizole: dosing, preparation and hemodialysis adjustments.
- EXTRIP. Methanol poisoning.
- EXTRIP. Ethylene glycol poisoning (2023 recommendations).
- Austin Clinical Toxicology Service. Fomepizole guideline (December 2024).
- Wu and Austin. Isopropanol toxicity. CMAJ (2026).
- CDC. Diethylene-glycol-contaminated medicine outbreak, Nigeria (2009).
- Prawira et al. Pediatric EG/DEG poisoning case series (2025).
- Besenhofer et al. Inhibition of diethylene glycol metabolism in rats (2010).
- EXTRIP. Salicylates: extracorporeal treatment recommendations.
- Utah Poison Control. Salicylate overdose treatment protocol (April 2025).
- EXTRIP. Valproic acid poisoning.
- RCH. Sodium valproate poisoning (2020).
- Queensland Poisons Information Centre. Levocarnitine (2023).
- Maryland Poison Center. Levocarnitine in valproic acid poisoning (2021).
- DailyMed. Divalproex: hyperammonemia and topiramate.
- DailyMed. Lantus: overdose and hypokalemia.
- DailyMed. Glucagon for injection: emergency administration and depleted glycogen.
- Utah Poison Control. Octreotide protocol (September 2024).
- RCH. Oral hypoglycaemic poisoning (December 2020).
- DailyMed. Levoleucovorin injection: rescue dosing and administration (Meitheal, revised August 2023).
- DailyMed. Leucovorin calcium injection: methotrexate rescue tables and route precautions.
- Ramsey et al. Glucarpidase consensus: infusion-specific algorithm (2018).
- EXTRIP. Methotrexate poisoning recommendations and systematic review (2022).
- Bielack et al. European consensus on delayed methotrexate elimination (2024).
- DailyMed. Voraxaze glucarpidase prescribing information.
- DailyMed. Vistogard uridine triacetate prescribing information.
- DailyMed. DigiFab digoxin immune Fab prescribing information.
- EXTRIP. Beta-adrenergic antagonist poisoning: drug-specific extracorporeal treatment recommendations.